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A B S T R A C T
Background
People with unstable angina and non-ST elevation myocardial infarction (UA/NSTEMI) are managed with a combination of medical
therapy, invasive angiography and revascularisation. Specifically, two approaches have evolved: either a ’routine invasive’ strategywhereby
all patients undergo coronary angiography shortly after admission and, if indicated, coronary revascularisation; or a ’selective invasive’
(also referred to as ’conservative’) strategy in which medical therapy alone is used initially, with a selection of patients for angiography
based upon evidence of persistent myocardial ischaemia. Uncertainty exists as to which strategy provides the best outcomes for these
patients. This Cochrane review is an update of a Cochrane review originally published in 2006, to provide a robust comparison of these
two strategies in the early management of patients with UA/NSTEMI.
Objectives
To determine the benefits and harms associated with the following.
1. A routine invasive versus a conservative or ’selective invasive’ strategy for the management of UA/NSTEMI in the stent era.
2. A routine invasive strategy with and without glycoprotein IIb/IIIa receptor antagonists versus a conservative strategy for the man-
agement of UA/NSTEMI in the stent era.
Search methods
We searched the following databases and additional resources up to 25 August 2015: the Cochrane Central Register of Controlled
Trials (CENTRAL) on the Cochrane Library, MEDLINE and EMBASE, with no language restrictions.
Selection criteria
We included prospective randomised controlled trials (RCTs) that compared invasive with conservative or ’selective invasive’ strategies
in participants with acute UA/NSTEMI.
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Data collection and analysis
Two review authors screened the records and extracted data in duplicate. Using intention-to-treat analysis with random-effects models,
we calculated summary estimates of the risk ratio (RR) with 95% confidence intervals (CIs) for the primary endpoints of all-cause death,
fatal and non-fatal myocardial infarction (MI), combined all-cause death or non-fatal MI, refractory angina and re-hospitalisation.
We performed further analysis of included studies based on whether glycoprotein IIb/IIIa receptor antagonists were used routinely.
We assessed the heterogeneity of included trials using Pearson χ² (Chi² test) and variance (I² statistic) analysis. Using the Grading
of Recommendations Assessment, Development and Evaluation (GRADE) approach, we assessed the quality of the evidence and the
GRADE profiler (GRADEPRO) was used to import data from Review Manager 5.3 (Review Manager) to create Summary of findings
(SoF) tables.
Main results
Eight RCTs with a total of 8915 participants (4545 invasive strategies, 4370 conservative strategies) were eligible for inclusion. We
included three new studies and 1099 additional participants in this review update. In the all-study analysis, evidence did not show
appreciable risk reductions in all-cause mortality (RR 0.87, 95% CI 0.64 to 1.18; eight studies, 8915 participants; low quality evidence)
and death or non-fatal MI (RR 0.93, 95%CI 0.71 to 1.2; seven studies, 7715 participants; low quality evidence) with invasive strategies
compared to conservative (selective invasive) strategies at six to 12 months follow-up. There was appreciable risk reduction in MI (RR
0.79, 95% CI 0.63 to 1.00; eight studies, 8915 participants; moderate quality evidence), refractory angina (RR 0.64, 95% CI 0.52 to
0.79; five studies, 8287 participants; moderate quality evidence) and re-hospitalisation (RR 0.77, 95% CI 0.63 to 0.94; six studies,
6921 participants; moderate quality evidence) with routine invasive strategies compared to conservative (selective invasive) strategies
also at six to 12 months follow-up.
Evidence also showed increased risks in bleeding (RR 1.73, 95% CI 1.30 to 2.31; six studies, 7584 participants; moderate quality
evidence) and procedure-related MI (RR 1.87, 95% CI 1.47 to 2.37; five studies, 6380 participants; moderate quality evidence) with
routine invasive strategies compared to conservative (selective invasive) strategies.
The low quality evidence were as a result of serious risk of bias and imprecision in the estimate of effect while moderate quality evidence
was only due to serious risk of bias.
Authors’ conclusions
In the all-study analysis, the evidence failed to show appreciable benefit with routine invasive strategies for unstable angina and non-
ST elevation MI compared to conservative strategies in all-cause mortality and death or non-fatal MI at six to 12 months. There was
evidence of risk reduction in MI, refractory angina and re-hospitalisation with routine invasive strategies compared to conservative
(selective invasive) strategies at six to 12 months follow-up. However, routine invasive strategies were associated with a relatively high
risk (almost double the risk) of procedure-relatedMI, and increased risk of bleeding complications. This systematic analysis of published
RCTs supports the conclusion that, in patients with UA/NSTEMI, a selectively invasive (conservative) strategy based on clinical risk
for recurrent events is the preferred management strategy.
P L A I N L A N G U A G E S U M M A R Y
Routine invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Background
People with prolonged or recurrent chest pain may have a condition called unstable angina (UA) or suffer a certain type of heart attack
called non-ST elevation myocardial infarction (NSTEMI). People with either of these two conditions may be managed by either one of
two treatment strategies: the routine invasive strategy, or the conservative or ’selective invasive strategy’. With the first approach, patients
have a catheter (a long, patent tube) inserted into the arteries that bring blood to the heart muscle itself, called the coronary arteries.
The main objective behind inserting this catheter (in other words, to perform a procedure called coronary angiography) is to look for
thickening and hardening of the vessel. If a significant narrowing or a complicated plaque is found, then the artery may be dilated by
inserting a balloon catheter that can be inflated wherever the vessel is particularly narrow, so as to open the vessel and improve blood
flow. The vessel is held open by inserting a metallic stent. In some cases, the region of vessel narrowing is not amenable to this approach
and surgery to bypass it is required. With the other, conservative or ’selective invasive’ strategy, patients are initially treated with drugs,
and only those who continue to suffer further chest pain or who demonstrate evidence of ongoing coronary artery narrowing via other
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non-invasive tests, such as stress testing or imaging, undergo coronary angiography and revascularisation if indicated. In this Cochrane
review, researchers examined the available evidence to determine which strategy is better.
Study characteristics
We included randomised controlled trials that compared routine invasive strategies to conservative strategies in patients with UA and
NSTEMI in the stent era. We searched the available literature up to 25 August 2015.
Key results
We included eight studies with 8915 participants: five trials were in the review version published in 2010, and three were new trials. Of
the included participants with UA and NSTEMI, there were 4545 in the invasive strategy arm and 4370 in the conservative strategy
arm. Evidence failed to show appreciable risk reduction in all-cause mortality and death or non-fatal myocardial infarction (MI) with
routine invasive management strategy compared to conservative strategies. There was appreciable risk reduction inMI, refractory angina
and re-hospitalisation with routine invasive strategies compared to conservative strategies, but this was associated with an increased risk
of procedure-related MI and bleeding complications.
Quality of evidence for primary outcomes
The quality of the evidence in this review update ranged from low quality to moderate quality. Low quality evidence was as a result of
serious risk of bias and uncertainty surrounding the effect, while moderate quality evidence was only due to serious risk of bias.
Conclusions
The debate continues as to which strategy is better. The invasive strategy reduces the incidence of further chest pain or re-hospitalisation.
Also, long-term follow-up from three studies suggests that it lowers the risk of a heart attack over the next three to five years. However,
the invasive strategy also is associated with double the risk of heart attack during or soon after initial treatment, as well as an increased
risk of bleeding. In summary, the published scientific research suggests that the invasive strategy may have particular benefit in those
patients who are at high risk for recurrent events, and that patients at low risk for a recurrent event may even suffer harm from such an
approach.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Routine invasive strategies versus selective invasive strategies (conservative) for UA/ NSTEM I infarction in the stent era
Participant or population: part icipants with UA/ NSTEMI in the stent era
Settings: hospital sett ing
Intervention: rout ine invasive strategies
Comparison: select ive invasive strategies (conservat ive)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Selective invasive strate-
gies (conservative)
Routine invasive strategies
Death
Follow-up: 6 to 12 months1
Study population RR 0.87
(0.64 to 1.18)
8915
(8 studies)
⊕⊕©©
low2,3
42 per 1000 36 per 1000
(27 to 49)
M oderate risk population
39 per 1000 34 per 1000
(25 to 46)
M yocardial infarction
Follow-up: 6 to 12 months1
Study population RR 0.79
(0.63 to 1)
8915
(8 studies)
⊕⊕⊕©
moderate2
78 per 1000 62 per 1000
(49 to 78)
M oderate risk population
89 per 1000 70 per 1000
(56 to 89)
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Death or non- fatal M yocar-
dial infarction
Follow-up: 6 to 12 months1
Study population RR 0.93
(0.71 to 1.2)
7715
(7 studies)
⊕⊕©©
low2,3
113 per 1000 105 per 1000
(80 to 135)
M oderate risk population
109 per 1000 101 per 1000
(77 to 131)
Refractory angina
Follow-up: 6 to 12 months1
Study population RR 0.64
(0.52 to 0.79)
8287
(5 studies)
⊕⊕⊕©
moderate2
325 per 1000 208 per 1000
(169 to 257)
M oderate risk population
129 per 1000 83 per 1000
(67 to 102)
Rehospitalisation
Follow-up: 6 to 12 months1
Study population RR 0.77
(0.63 to 0.94)
6921
(6 studies)
⊕⊕⊕©
moderate2
286 per 1000 220 per 1000
(180 to 269)
M oderate risk population
122 per 1000 94 per 1000
(77 to 115)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; UA: unstable angina; NSTEM I: non ST segment myocardial infarct ion.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 Intermediate end points.
2 Downgraded by one due to possible risk of bias due to lack of blinding.
3 Downgraded by one due to imprecision with ef fect size overlapping the line of no ef fect and appreciable benef it or harm.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Diagnosis of acute coronary syndromes
Acute coronary syndrome (ACS) encompasses three disorders of
related aetiology: ST-elevation myocardial infarction (STEMI);
non-STEMI (NSTEMI); and unstable angina (UA).Management
of STEMI differs from that for UA and NSTEMI, which can
be considered a single clinical entity (UA/NSTEMI). The patho-
genesis of UA/NSTEMI involves five non-exclusive causative fac-
tors: non-occlusive thrombus on pre-existing plaque; dynamic
obstruction; progressive mechanical obstruction; inflammation;
and secondary UA associated with increased cardiac workload
(Braunwald 1998). Of these factors, thrombus formation on pre-
existing plaque, which is an acute plaque change, is the most
common. Indeed, most patients with ACS have an acute change
in coronary atherosclerotic plaques, with STEMI usually associ-
ated with complete occlusion of the involved vessel(s) (DeWood
1980) and UA/NSTEMI usually associated with subtotal occlu-
sion (DeWood 1986; TIMI-IIIA 1993). The distinction between
UA and NSTEMI depends on the presence of myocardial infarc-
tion (MI), as determined by markers of myocardial damage such
as troponin I (TnI), troponin T (TnT) and creatine kinase-my-
ocardial band (CK-MB).
Compared to STEMI, NSTEMI has a lower 30-day mortality
rate, but more recurrent ischaemia and a similar one-year mortal-
ity rate (Armstrong 1998). UA/NSTEMI is much more common
than STEMI; in the USA, for example, 1.4 million patients per
year are admitted to hospital with ACS, approximately 70% of
them with UA/NSTEMI (Rosamond 2008). Whereas emergency
percutaneous coronary revascularisation is now a commonly-used
therapy for treating STEMI (Antman 2004; Cucherat 2003), the
role of angiography and possible subsequent revascularisation is
less clear in UA/NSTEMI patients. Treatment of UA/NSTEMI
initially involves medical therapy followed by one of two varia-
tions on the management strategy, which results in differing rates
of angiography and revascularisation. In this Cochrane review up-
date we review the medical therapies for UA/NSTEMI briefly be-
fore we focus on the management strategies of patients with UA/
NSTEMI.
Initial medical management of UA/NSTEMI
Medical treatments, as outlined in the American College of Car-
diology Foundation (ACCF) and American Heart Association
(AHA) (Anderson 2007; Jneid 2012) and European Society of
Cardiology (ESC) guidelines (Hamm 2011), fall into the two
major categories: anti-ischaemic and anti-platelet/anti-coagula-
tion. Anti-ischaemic therapies include bed rest, nitroglycerin, beta
blockers (or certain non-dihydropyridine calcium antagonist if
beta blockers are contraindicated) and angiotensin-converting en-
zyme (ACE) inhibitors. Anti-platelet or anti-coagulation therapies
include aspirin, P2Y12 receptor inhibitor treatment (clopidogrel,
prasugrel and ticagrelor), heparin and glycoprotein IIb/IIIa recep-
tor antagonists. Published randomised clinical trials support the
use of most of these specific therapies. Among the anti-ischaemic
treatments, beta blockers have proven efficacy in patients with
evolvingMI (Hjalmarson 1982; Yusuf 1988), as well as in patients
with UA/NSTEMI (Gottlieb 1986;Muller 1984; Théroux 1985).
Non-dihydropyridine calcium channel antagonists have proven
efficacy in ACS (Boden 1991; Gibson 1986; Pepine 1998; Tijssen
1987), and are particularly useful in patients with contraindica-
tions to beta-blockers. Both the early and late administration of
ACE inhibitors can be beneficial for MI (EUROPA 2003; HOPE
2000; Rodrigues 2003). Of the anti-platelet or anti-coagulation
treatments, aspirin exhibits a consistent benefit for UA/NSTEMI
as demonstrated in several clinical trials (Cairns 1985; Lewis 1983;
RISC 1990; Theroux 1988). Similarly, clopidogrel is a benefi-
cial adjunct to aspirin (CURE 2001). Subsequently, prasugrel,
TRITON-TIMI 38, and ticagrelor, PLATO, have been identified
as alternatives to clopidogrel. Heparin, in its various forms, or fon-
daparinux are also beneficial in UA/NSTEMI (Gurfinkel 1995;
Mehta 2008; Neri Serneri 1990; RISC 1990; Theroux 1993).
The glycoprotein IIb/IIIa receptor antagonists have proven effi-
cacy in the medical treatment of UA/NSTEMI (Boersma 2002;
PRISM-PLUS Trial; PURSUIT 1998; Roffi 2002; Topol 1999).
However, this class of drugs appears to have differential effects
depending on the patients’ risk level and bleeding propensity, and
high-risk patients obtain the greatest benefit; consequently, their
use should be highly-selective (ACUITY; EARLYACS 2009). The
glycoprotein IIb/IIIa receptor antagonists warrant special mention
regarding their use in invasive procedures. We expand upon this
concept later in this review update.
Management following initial medical
treatment: what is the role of early coronary
angiography and revascularization?
Two different treatment strategies may be adopted after the initial
medical treatment of UA/NSTEMI.
1. A routine invasive strategy of coronary angi ography and, if
indicated, revascularisation in most or all patients who have no
contraindication to such an approach.
2. A ’selective invasive’ or ’ischaemia guided’ (conservative)
strategy, in which patients undergo coronary angiography and
revascularisation only if there is evidence of recurrent ischaemia.
Examples are recurrent infarction, angina at rest, dynamic ST
changes on electrocardiograph (ECG), and definitive inducible
ischaemia on provocative testing.
Proponents of the routine invasive strategy argue that the early
determination of coronary anatomy can be used to tailor revascu-
larisation therapy, avoid lengthy hospital stays and prevent further
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events. Those with significant coronary disease evident on angiog-
raphy can be treated expeditiously according to their angiographic
findings, which may include revascularisation via percutaneous
coronary intervention (PCI) comprised of coronary angioplasty
and coronary stenting, or coronary artery bypass grafting (CABG).
Proponents of the conservative or ’selective invasive’ strategy ar-
gue that medical therapy can stabilise patients. Stress testing can
identify patients at risk for future events and who would therefore
benefit most from an invasive intervention. This strategy may also
limit the costs and complications of invasive procedures. The ev-
idence for the relative advantages and disadvantages of these two
approaches is the subject of this Cochrane review.
Interpretation of the evidence from trials:
changes in contemporary clinical practice
In routine clinical practice, the outcomes of invasive coronary
procedures vary depending upon a number of factors, including
clinical expertise (Singh 2000), volume of procedures performed
(Magid 2000), and methods and protocols used, especially regard-
ing pharmacological and procedural co-interventions. Of partic-
ular importance in contemporary practice is the use of coronary
artery stents (Al Suwaidi 2004), which improves outcomes and re-
duces complications when used with invasive procedures. Stenting
is associated with fewer major adverse cardiovascular events and
a reduced need for emergency cardiac surgery (Al Suwaidi 2004).
Specifically, the reduction in target vessel revascularisation associ-
ated with stenting is of particular relevance to trials with longer
durations of follow-up.
Upstream glycoprotein IIb/IIIa receptor antagonist use is con-
troversial. Though these drugs initially seemed beneficial (EPIC
1994; EPILOG 1997; EPISTENT 1998; Karvouni 2003;
Simoons 1997), their routine application has been associated
with an increased risk of non-life-threatening bleeding (ACUITY;
EARLY ACS 2009), which has resulted in a paradigm shift from
routine to highly-selective use. In the ACUITY study, patients
with UA/NSTEMI treated with an early invasive strategy, bi-
valirudin without routine glycoprotein IIb/IIIa receptor antago-
nists, demonstrated significantly reduced rates of major bleeding
with non-inferior outcomes in ischaemia endpoints compared to
standard heparin or bivalirudin with mandatory glycoprotein IIb/
IIIa receptor antagonists (Stone 2006; Stone 2007). However, the
substitution of bivalirudin for heparin with glycoprotein IIb/IIIa
receptor antagonists probably should not be undertaken unless
patients have been pretreated with a thienopyridine prior to an-
giography (Stone 2006).
Why it is important to do this review
UA/NSTEMI is a common hospital presentation and carries a
significant risk of mortality and recurrent ischaemic events. Older
landmark meta-analyses (Bavry 2006; Mehta 2005) include pre-
stent era trials anddonot considermore recently published studies,
and thus limit their application to contemporary management of
this serious disease. This Cochrane review evaluates the relative
merits of the two above-noted strategies in the modern era with
relevance to patients, physicians and healthcare systems.
O B J E C T I V E S
Todetermine the benefits and harms associatedwith the following.
1. A routine invasive versus a conservative or ’selective invasive’
strategy for the management of UA/NSTEMI in the stent era.
2. A routine invasive strategy with and without glycoprotein
IIb/IIIa receptor antagonists versus a conservative strategy for the
management of UA/NSTEMI in the stent era.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only considered studies undertaken in the stent era for in-
clusion. If we had included non-stent studies, the analysis would
underestimate the benefits of a routine invasive strategy on end-
points such as recurrent angina and rehospitalisation (e.g. due to
chest pain). We included randomised controlled trials (RCTs) that
compared invasive and selectively invasive strategies in participants
with unstable angina and non-ST elevation myocardial infarction
(UA/NSTEMI), and measured at least one of this review’s out-
comes. The revascularisation approaches in the included studies
were percutaneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG), as required. We investigated the effect of
glycoprotein IIb/IIIa receptor antagonist use on outcomes further
by undertaking two separate analyses on trials according to routine
versus selective use of glycoprotein IIb/IIIa receptor antagonists
during PCI. Thus, the analyses we undertook were as follows.
1. All studies that deployed stents routinely in
revascularisation procedures using PCI, regardless of
glycoprotein IIb/IIIa receptor antagonist use.
2. Stents and glycoprotein IIb/IIIa receptor antagonists
deployed routinely in revascularisation procedures using PCI.
3. Stents deployed routinely in revascularisation procedures
using PCI with selective glycoprotein IIb/IIIa receptor
antagonists use.
It is important to note that, in recent years, a number of studies
have focused on the optimal timing of an invasive strategy. While
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these studies fulfil many of the criteria for inclusion, often they
did not randomise patients to a medically-managed conservative
or ’selective invasive’ strategy. Consequently, we have generally
excluded these studies from the current analysis.
Types of participants
Men and women, at least 18 years of age, who had an episode
of angina with an accelerating pattern of pain at rest. The index
episode of pain must have occurred within 72 hours of randomi-
sation. Furthermore, the patients must have exhibited at least one
of the following.
1. New ST depression.
2. Transient (< 20 minute) ST elevation.
3. Ischaemic T-wave inversion or T-wave inversion in at least
two contiguous leads.
4. Elevated levels of cardiac markers; e.g. troponin’s or creatine
kinase-myocardial band (CK-MB).
5. Coronary artery disease (CAD), as determined by a history
of catheterisation, revascularisation, or acute coronary syndromes
(ACS).
The included studies generally excluded patients if they had any
of the following.
1. Persistent ST elevation (i.e. > 20 minutes).
2. Secondary causes of acute myocardial ischaemia (e.g.
anaemia, thyrotoxicosis, acute pulmonary infection, fever,
tachyarrhythmias, uncontrolled hypertension).
3. Secondary causes of cardiac biomarker elevation or altered
kinetics (e.g. renal insufficiency, acute non-cardiac disease etc.).
4. Serious systemic disease or major co-morbidities that would
preclude an invasive approach.
5. Severe congestive heart failure or cardiogenic shock.
6. Arrhythmias that required immediate catheterisation.
7. Refractory symptoms.
8. Intolerance of anticoagulation and anti-platelet therapy.
9. Coronary revascularization procedure within the previous
30 days.
Types of interventions
All patients with UA/NSTEMI were initially treated with some
or all of the medical therapies we discussed in the ’Background’
section; we have summarised these in Table 1. Following initial
medical therapy, patients were randomised to either routine or se-
lective invasive treatment. The two treatment strategies differed
with regard to the use of angiography and subsequent revascular-
isation rates.
The two management strategies compared were as follows.
1. Routine invasive strategy: routine angiography with or
without revascularisation in all patients. This was performed in
all eligible patients unless they had contraindications to
angiography.
2. Conservative or ’selective invasive’ strategy: angiography
with or without revascularisation only in eligible patients with
evidence of cardiac ischaemia; e.g. recurrent ischaemia, dynamic
electrocardiograph (ECG) changes or a positive stress test.
Revascularisation modalities included PCI or CABG, depending
on the angiographic findings. CABG is indicated in lieu of PCI
when any one of the following criteria is met.
• Three vessel disease and an ejection fraction (EF) of less
than 0.50.
• Two vessel disease with proximal left anterior descending
involvement and EF of less than 0.50 or ischaemia.
• Left main CAD.
Types of outcome measures
Primary outcomes
1. Death: all causes.
2. Myocardial infarction (MI) (this endpoint only included
non-fatal MI in the review protocol, but the review includes fatal
and non-fatal MI).
3. Death (all causes) or non-fatal MI.
4. Refractory angina.
Secondary outcomes
1. Rehospitalisation for ACS.
2. Complications of angiography or revascularisation (e.g.
bleeding, procedure-related MI, stroke).
Differentiating peri-PCI cardiac biomarker leaks from the out-
come measure ’non-fatal myocardial infarction’ warrants further
comment. A universal definition of MI, including peri-procedural
MI, has only recently been adopted and defines peri-procedural
MI as a biomarker increase to three times the upper reference limit
(Thygesen 2007). Unfortunately, as summarised inTable 2, the in-
cluded studies inconsistently defined peri-procedural MI and this
limited the interpretation of this outcome data across the included
trials. The TACTICS-TIMI 18, OASIS 5 and Italian Elderly ACS
definitions most closely match the current universal definition.
Furthermore, not all included studies involved the routine mea-
surement of cardiac biomarkers following PCI. We have discussed
this point further under the heading ’Outcomes’.
Search methods for identification of studies
The previous version of this review (Hoenig 2010) included: the
Cochrane Central Register of Controlled Trials (CENTRAL) (Is-
sue 1 of 12, 2008) on the Cochrane Library, MEDLINE (1996
to February 2008) and EMBASE (1996 to February 2008). The
review applied a restriction of 1996 onwards because of low rates
of stent use prior to that year (see Appendix 1 for search strategies).
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This review update utilised similar search strategies for CEN-
TRAL (Issue 7 of 12, 2015) on the Cochrane Library, MEDLINE
(OVID, 1946 to August week 3, 2015) and EMBASE (OVID,
1980 to 2015 week 33), restricted from 2008 through to the date
of the searches, 25 August 2015 (see Appendix 2 for search strate-
gies). We searched the reference lists of all retrieved articles and
contacted experts in the field to identify additional potentially-
eligible studies. We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors of a previous version of this review (Hoenig
2010)(MRH, JAD) identified and independently selected studies
published between 1996 and 2008 for inclusion. Two authors of
this review update (JPF, DLW) identified studies published be-
tween 2008 and 2015. We considered a study to be eligible for
inclusion if it prospectively enrolled eligible participants with an
acute presentation of UA/NSTEMI and randomised their man-
agement to either a routine invasive strategy or conservative/’se-
lective invasive’ strategy in patients with an acute presentation of
UA/NSTEMI. We have mentioned specific exclusion criteria in
the ’Types of studies’ section.
Data extraction and management
Two of the original review authors (MRH, JAD) extracted data
from the 1996 to 2008 searches independently onto data extrac-
tion sheets. They resolved any disagreements first by consensus
and then by consultation with CNA and IAS. We updated the lit-
erature searches for the period 2008 to 2015. Two review authors
(JPF, DLW) independently extracted relevant data using double
data entry.
’Risk of bias’ assessment
Two review authors independently assessed the risk of bias in all
included studies. Please refer to the ’Characteristics of included
studies’ tables for the quality assessment guidelines for the included
studies.
Statistical considerations
We analysed data on an ITT basis. Where appropriate, we com-
bined data from all trials using the meta-analysis software in Re-
view Manager (RevMan) (RevMan 2014). All outcome measures
of this Cochrane review were dichotomous. We combined data
using a random-effects model to determine a summary estimate
of the risk ratio (RR) with a 95% confidence interval (CI). We
assessed heterogeneity using the Pearson χ² (Chi²) test (P < 0.10)
for all endpoints and the I² statistic for selected endpoints (Higgins
2003).We displayed the I² statistic on the forest plots for all analy-
ses. Furthermore, we performed sensitivity analysis for various pre-
specified variables that may present sources of inter-study hetero-
geneity. Since this meta-analysis contained a small number of in-
cluded studies and we previously identifiedmany potential sources
of heterogeneity (Hoenig 2010), we did not undertake meta-re-
gression. As such, we felt that individual patient data meta-analysis
would be more appropriate (Thompson 2005). This also would
avoid aggregation bias. Given the discrepant definitions of MI be-
tween the included studies (Table 2), we used mortality at end of
follow-up when we assessed publication bias or heterogeneity via
sensitivity analysis. As stated under the ’Types of studies’ section,
we analysed all included studies further by assigning them to one
of two analyses, depending on the routine use of glycoprotein IIb/
IIIa receptor antagonists. We compared the invasive strategy ver-
sus the conservative strategy within each analysis.
Summary of findings
The GRADE approach was employed to interpret findings and
the GRADE profiler (GRADEPRO) allowed us to import data
from Review Manager 5.3 (Review Manager) to create ’Summary
of findings’ tables.
R E S U L T S
Description of studies
The original literature search performed for this review (1996 to
2008) yielded 2221 hits (Hoenig 2010). Of these, we selected 31
papers that reported on 14 studies for closer attention. We ex-
cluded one study because it was based on a registry and hence
contained observational data (MITI 2000). We excluded another
study because it was a post-hoc analysis of a trial that compared
hirudin to heparin in acute coronary syndrome (ACS) patients
(GUSTO2b 2003). We excluded four trials because they were
undertaken in the pre-stent era or did not encourage the rou-
tine use of stents in the invasive strategy (MATE 1998; TIMI-3b;
VANQWISH 1998; Zhao 2005). Moreover, some studies in-
cluded patients with ST elevation myocardial infarction (STEMI)
but did not report outcomes separately for unstable angina (UA)/
non-ST elevation myocardial infarction (NSTEMI) (Eisenberg
2005; MATE 1998). As stated earlier, studies from the pre-stent
era underestimate the value of the invasive strategy and are irrele-
vant to current practice. Also, we excluded two studies because of
inappropriate participant selection or trial design (ISAR-COOL;
TRUCS 2000). More details on the excluded studies can be found
in the ’Characteristics of excluded studies’ table. We deemed five
studies appropriate for inclusion and we have described these in
the ’Characteristics of included studies’ table. We analysed these
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five studies together in Analysis 1. Two studies used a glycoprotein
IIb/IIIa antagonist routinely in the routine invasive arm (ICTUS;
TACTICS-TIMI 18), and we analysed these two studies together
via the prespecified Analysis 2 (see the ’Types of studies’ section).
The three remaining studies satisfied this Cochrane review’s stent
requirement but did not routinely use glycoprotein IIb/IIIa an-
tagonists in participants randomised to the routine invasive strat-
egy. We analysed these together as Analysis 3 (FRISC-II; RITA-3;
VINO).
The literature search update (2008 to 2015) yielded 1929 hits,
of which 27 were potentially relevant articles. Of these, we added
five articles, which related to three studies (Italian Elderly ACS;
LIPSIA-NSTEMI; OASIS 5), to the previous analysis. The Italian
Elderly ACS and OASIS 5 studies were also relevant to Analy-
sis 2, and the LIPSIA-NSTEMI trial was relevant to Analysis 3.
We excluded a number of important randomised controlled trials
(RCTs) from the update due to the absence of randomisation to a
management arm consistent with the ’selective invasive’ strategy as
defined in thisCochrane review.These studies generally focused on
the optimal timing of an invasive strategy (e.g. ABOARD; ELISA;
ISAR-COOL; OPTIMA; TIMACS; Zhang 2010), or optimal
use of antithrombotic medication (e.g. ACUITY; EARLYACS;
PLATO; TRITON-TIMI 38). A published conference abstract,
Dimitrov 2013, eluded to a potentially relevant study. However,
as the full text publication was unavailable at the time of the lit-
erature search, we classified this study as ’ongoing’ and excluded
it from the analyses (see the ’Characteristics of ongoing studies’
section).
Design
All included studies were RCTs. Due to the procedural nature
of the intervention, we presumed that the participants and treat-
ing clinicians were not blinded to the intervention. However, a
blinded committee could assess outcomes. The ’Characteristics of
included studies’ table describes the trial design features and in-
cludes information on intention-to treat (ITT) analysis and losses
to follow-up.
Populations
The included studies were heterogeneous in their participant se-
lection criteria. The inclusion criteria were comprised of different
combinations of the following core criteria: chest pain, electrocar-
diograph (ECG) changes, increased level(s) of cardiac marker(s)
or a documented history of coronary artery disease (CAD). We
have outlined the specific criteria for each included study in the
’Characteristics of included studies’ table. Clearly, since the in-
cluded studies used different criteria, the trials randomised partic-
ipants at different levels of risk. Elevated troponin levels (Antman
1996; Galvani 1997; Lindahl 1996) or ECG changes (Cannon
1997) forebode a worse prognosis for unstable angina and non-
ST elevation myocardial infarction (UA/NSTEMI). As such, tri-
als that recruited these participants could be expected to exhibit
higher event rates. For example, the VINO study, which had the
highestmortality rate (26.8%per year of follow-up) and the Italian
Elderly ACS study, which had the second highest mortality rate
(13.8% per year follow-up), randomised participants who had
chest pain, ECG changes and elevated cardiac markers; whereas
in TACTICS-TIMI 18, 27% of the trial participants had acceler-
ating or prolonged chest pain with a history of CAD as the sole
entry criteria. Additionally, the Italian Elderly ACS only included
participants who were 65 years of age or older, with the atten-
dant increased morbidity and mortality that comes with aging. In
contrast, the entry criteria for the RITA-3 study were explicitly
aimed at intermediate-risk participants and theOASIS 5 substudy
exclusively recruited female participants.
Interventions
Within the routine invasive strategy, all participants were ran-
domised to receive angiography, regardless of symptom status. In
contrast, with the conservative/’selective invasive’ strategy, angiog-
raphy only was performed in participants with clinical or inves-
tigational evidence of ischaemia. It is important to note that an-
giography is a component of both strategies, and that angiography
in the conservative arm did not represent a ’cross-over’, as long as
it was preceded by myocardial ischaemia or evidence of CAD.
Time to interventions
The times to angiography after randomisation in the routine in-
vasive arms were: mean 6.2 hours in VINO, median 22 hours
in TACTICS-TIMI 18, median 23 hours in ICTUS, mean 24
hours in the Italian Elderly ACS, median two days in RITA-3,
median 51 hours in OASIS 5 and mean four days in FRISC-II.
The invasive strategy in the LIPSIA-NSTEMI trial included both
an immediate invasive strategy and an early invasive strategy with
respective mean randomisation to sheath insertion times of 1.1
and 18.3 hours.
The FRISC-II trial authors cited observational data to justify de-
layed angiography and postulated that a period of “plaque passi-
vation” prior to angiography would be beneficial. However, the
ISAR-COOL trial subsequently compared an ’early invasive’ (an-
giography within six hours of randomisation) to ’delayed inva-
sive’ (angiography in three to five days) strategy in UA/NSTEMI
patients and found that early angiography produced superior
outcomes. Since that time, a number of RCTs have evaluated
the optimal timing of an invasive approach (ABOARD; ELISA;
LIPSIA-NSTEMI; OPTIMA; TIMACS; Zhang 2010). However,
at present, there is insufficient evidence to indicate the optimal
time for invasive management in general populations and such a
discussion is beyond the scope of this Cochrane review.
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Criteria for ischaemia
There were important differences between the included trials in
the criteria for ischaemia that mandated angiography within the
selectively invasive arm. In particular, the FRISC-II criteria were
widely criticised for being more stringent than those of the other
studies, thereby exaggerating any benefit conferred by the invasive
strategy. Furthermore, FRISC-II did not utilise nuclear imaging or
pharmacologic stress testing in its selectively invasive strategy arm.
Indeed, application of the FRISC-II criteria to the VANQWISH
1998 study, which recruited similar participants, suggests that sig-
nificant CADwas under-detected in the selectively invasive arm of
the FRISC-II study (Goyal 2002). Similarly, the LIPSIA-NSTEMI
trial applied strict criteria for intervention in the conservative arm,
including evidence of refractory ischaemia by clinical, ECG and
stress testing, and an ejection fraction (EF) via echocardiography
of less than 45%. Consequently, 70% of those randomised to
the selectively invasive arm underwent an invasive strategy (versus
84% amongst those randomised to receive an invasive strategy).
Conversely, the Italian Elderly ACS did not require an objective
ischaemia measure and relied on symptoms alone. This resulted in
lower rates of invasive management in the conservative arm (31%
versus 58% amongst those randomised to an invasive strategy).
Outcomes
Commonly reported outcomes included death, myocardial infarc-
tion (MI) and recurrent angina. Death was reported as all-cause
mortality. The definition of MI varied between the included stud-
ies, but included a combination of chest pain, ECG changes and
elevated cardiac biomarkers. Not all studies reported peri-percu-
taneous coronary intervention (peri-PCI) cardiac biomarker leaks
without other criteria as an endpoint, but were included as a sa-
fety outcome where data were available. We have summarised the
variable definitions of MI in Table 2, which show that some stud-
ies required clinical or ECG changes, or both, for MI endpoints,
whereas others only required an increased cardiac marker. Impor-
tantly, the ICTUS andLIPSIA-NSTEMI trial protocolsmandated
the routinemeasurement of creatine kinase-myocardial band (CK-
MB) after PCI, and peak levels constituted the endpoint of MI
for both and the primary outcome for the LIPSIA-NSTEMI trial.
Such an assessment has the benefit of allowing quantification of
overall myocardial necrosis, including that associated with the in-
tervention itself. However, the significance of peri-PCI biomarker
leaks is a subject of considerable debate (Bhatt 2005; Cutlip 2005).
The other included trials did not specify the routine measurement
of CK-MBafter PCI per protocol. Fortunately the ICTUS trial au-
thors reported ’spontaneous’ and ’peri-procedural’ MI as separate
endpoints (de Winter 2005; Hirsch 2007; Windhausen 2007b).
Extraction of data from ICTUS, which combined spontaneous
and procedural MI into a single MI endpoint, caused significant
heterogeneity in a previous version of this meta-analysis (Hoenig
2010). Hence, to maximize consistency between trials, we anal-
ysed ’spontaneous’ MI from the ICTUS trial with our MI end-
point and reported peri-procedural MI as a safety endpoint. This
minimised heterogeneity during meta-analysis and also is justifi-
able since the significance of peri-procedural biomarker leaks is
still a subject of contention. Fortunately, endpoints such as death
are indisputable. Follow-up was six months in TACTICS-TIMI
18, VINO and LIPSIA-NSTEMI; one year in the Italian Elderly
ACS; two years in the OASIS 5 substudy; three years for MI but
four years for mortality in ICTUS; five years in FRISC-II; and five
years in RITA-3. We have summarised the characteristics of the
included studies in the ’Characteristics of included studies’ table
and in Table 1.
Risk of bias in included studies
We summarised the risk of bias of the included studies in the
’Characteristics of included studies’ table, Figure 1 and Figure 2.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged six of the included studies to be of low risk of bias as they
generated the random sequence adequately (FRISC-II; ICTUS;
Italian Elderly ACS; LIPSIA-NSTEMI; OASIS 5; VINO). Two
trials are of unclear risk of bias for random sequence generation
(RITA-3; TACTICS-TIMI 18) as they did not provide details on
the method of randomisation.
All trials were judged to be of low risk of allocation concealment.
Blinding
All included studies were judged to be of high risk of performance
bias. The blinding of outcome assessors was done in three trials
(ICTUS; Italian Elderly ACS; OASIS 5) and they were therefore
judged to be of low risk detection bias.One trial (TACTICS-TIMI
18) was of unclear risk of bias in this domain and four trials (
FRISC-II; LIPSIA-NSTEMI; RITA-3; VINO) were judged to be
of high risk of bias as outcome assessors were not blinded.
Incomplete outcome data
All trials were judged to be of low risk of attrition bias.
Other potential sources of bias
We judged four of the studies (FRISC-II; Italian Elderly ACS;
RITA-3; VINO) to be at low risk of other biases and the other four
studies (ICTUS; LIPSIA-NSTEMI; OASIS 5; TACTICS-TIMI
18) at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Routine
invasive strategies versus selective invasive strategies (conservative)
for unstable angina and non-ST elevation myocardial (UA/
NSTEMI) infarction in the stent era; Summary of findings
2 Routine invasive strategies versus selective invasive strategies
(conservative) for unstable angina and non-ST elevation
myocardial infarction (UA/NSTEMI) in the stent era
The baseline participant characteristics were equivalent between
the two randomised groups across all included studies. We anal-
ysedTACTICS-TIMI 18, ICTUS andLIPSIA-NSTEMI together
in Analysis 2, since they involved the routine use of both glycopro-
tein IIb/IIIa receptor antagonists and stents. Analysis 3 included
studies that only used stenting routinely, and included RITA-3,
FRISC-II, the Italian Elderly ACS, the OASIS 5 substudy and
VINO. Since the trials reported outcomes after different dura-
tions of follow-up, we categorised the endpoints for meta-analysis
as being index, early, intermediate or late. ’Index’ endpoints indi-
cate follow-up over the course of the initial hospitalisation. ’Early’
endpoints indicate a follow-up of up to four months. ’Intermedi-
ate’ endpoints indicate a follow-up from six to 12 months. ’Late’
endpoints indicate a follow-up greater than or equal to two years.
In studies that supplied endpoints at various time points within
a given category, we used the latest follow-up outcomes. For ex-
ample, if a trial provided outcomes at six and 12 months of fol-
low-up, we used the 12-month data for intermediate analysis. In
the ’Summary of findings’ table, we reported an all-study analysis
that involved all included studies for each outcome. This all-study
analysis was seen in studies that reported six to 12 months follow-
up period (i.e. intermediate endpoints).
Analysis 1: studies that deployed stents routinely in
revascularisation procedures using PCI, regardless of
glycoprotein IIb/IIIa receptor antagonist use
This analysis included all eight studies undertaken in the stent era,
regardless of glycoprotein IIb/IIIa receptor antagonist use (FRISC-
II; ICTUS; Italian Elderly ACS; LIPSIA-NSTEMI; OASIS 5 sub-
study; TACTICS-TIMI 18; RITA-3; VINO). The commonly re-
ported outcomes for this analysis are presented in Summary of
findings’ table 1 (Summary of findings for the main comparison)
and complications of angiography or revascularization in Sum-
mary of findings’ table 2 (Summary of findings 2).
Death: all causes (index, early, intermediate, late)
Risk of index death significantly increased with a routine inva-
sive versus conservative or selective invasive strategy (risk ratio
(RR) 1.54, 95% confidence interval (CI) 1.02 to 2.34; six trials,
8094 participants; Analysis 1.1). Early (RR 1.18, 95% CI 0.70
to 2.00; four trials, 4345 participants; Analysis 1.2), intermediate
(RR 0.87, 95% CI 0.64 to 1.18; eight trials, 8915 participants;
Analysis 1.3) and late (RR 0.90, 95% CI 0.76 to 1.08; three tri-
als, 5467 participants; Analysis 1.4) death were not significantly
affected by an invasive strategy. There was no evidence of any het-
erogeneity in inter-study effect sizes across all time points for this
endpoint.
The death rates standardised to years of study duration, shown in
Table 1, were 1.1% to 2.8% per year for the OASIS 5 substudy,
RITA-3, FRISC-II and ICTUS; whereas TACTICS-TIMI 18 had
a rate of 7%; the Italian Elderly ACS study and LIPSIA-NSTEMI
trial 13% to 14%; and VINO had a rate of 27%. For the most
part, the levels of risk were concordant with the inclusion crite-
ria employed by each study, as described in the ’Characteristics of
included studies’ table, with the exception of ICTUS. As already
discussed, mortality increases as troponin concentrations increase
in patients with ACS (Antman 1996). The ICTUS trial exclusively
enrolled participants with a troponin T (TnT) greater than 0.03
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ng/mL and, as such, would be expected to observe a higher mor-
tality rate. Indeed, in TACTICS-TIMI 18, the six-month mor-
tality rate for participants with a TnT greater than 0.01 ng/mL
was 4% (Morrow 2001). Since the ICTUS trial recruited partici-
pants with a TnT greater than 0.03 ng/mL and had a longer dura-
tion of 12 months, the standardised mortality would be expected
to be greater than 4%. Indeed, in FRISC-II, participants with a
TnT value greater than 0.03 ng/mL had a 12-month mortality
rate of 4.2% (Diderholm 2002). Hence, the ICTUS participants
appear to have experienced a lower than expected event rate, based
upon the event rates reported for other included trials. Differences
between trials in baseline medical therapy do not appear to ex-
plain why mortality in the ICTUS trial was less than the other tri-
als.High rates of background medical therapy seen in both ICTUS
and TACTICS-TIMI 18. This observation highlights the impor-
tance of global risk stratification over the selection of a single high-
risk characteristic when predicting the risk of future events.
MI (index, early, intermediate, late)
The incidence of MIs during the index hospitalisation was not
significantly affected by an invasive strategy (RR 1.08, 95% CI
0.65 to 1.80; seven trials, 8694 participants; Analysis 1.5), though
significant heterogeneity was identified at this time point (P =
0.003, I² statistic = 70%). Possible reasons for this heterogeneity
include the use of glycoprotein IIb/IIIa receptor antagonists in
TACTICS-TIMI 18 and the unique definition of MI the VINO
trial authors used, which excluded any events within the first 72
hours of randomisation (Table 2). Both early (RR 0.68, 95% CI
0.43 to 1.08; four trials, 4345 participants; Analysis 1.6) and in-
termediate (RR 0.79, 95% CI 0.63 to 1.00; eight trials, 8915 par-
ticipants; Analysis 1.7) MI endpoints revealed a non-significant
trend towards reduction with an invasive strategy. Interestingly,
the previous version of this review, Hoenig 2010. identified sta-
tistically significant reductions at the early and intermediate end-
points associated with an invasive versus conservative strategy, so
that the current analysis represents a reduced effect. Late MI rates
were drawn from three studies with these data - FRISC-II (five
years), RITA-3 (five years) and ICTUS (three years) - and as in
the previous meta-analysis, they remained significantly decreased
in those treated invasively (RR 0.78, 95% CI 0.67 to 0.92; three
trials, 5467 participants; Analysis 1.8).
Death (all causes) or non-fatal MI (index, early,
intermediate, late)
Index death or non-fatal MI, as a composite outcome, was not de-
creased in those treated via a routine invasive approach (RR 1.14,
95% CI 0.59 to 2.21; four trials, 6618 participants; Analysis 1.9);
however, we noted significant heterogeneity (P = 0.001, I² statistic
= 81%) and possible reasons include those already discussed for
components of the composite outcome. Early death or non-fatal
MI, based on 30-day TACTICS-TIMI 18 data and VINO data,
was significantly decreased with an invasive strategy (RR 0.64,
95%CI 0.45 to 0.92; two trials, 2351 participants; Analysis 1.10).
We observed a trend towards a decreased incidence of interme-
diate death or non-fatal MI, again as a composite outcome, with
the routine invasive strategy and included data from all included
studies except for ICTUS (RR 0.93, 95% CI 0.71 to 1.20; seven
trials, 7715 participants; Analysis 1.11). Again, as was the case
for the intermediate MI component of this composite outcome,
we noted heterogeneity (P = 0.007, I² statistic = 66%). As with
intermediate MI alone (see the previous paragraph), this repre-
sents a loss of significance relative to the previous version of this
review (Hoenig 2010), due to the influence of the OASIS 5 sub-
study and LIPSIA-NSTEMI studies. Late death or non-fatal MI
was not significantly decreased (RR 0.89, 95% CI 0.73 to 1.08;
three trials, 5467 participants; Analysis 1.13). The late follow-up
for this composite endpoint was perhaps less important, given the
independent benefit observed for the MI endpoint at late follow-
up and the ’dilution’ of this effect observed with incorporation of
mortality into a composite outcome.
Four included studies reported gender-specific data for males and
five studies reported it for females, and subanalysis of interme-
diate death or non-fatal MI demonstrated a statistically-signifi-
cant benefit of a routine invasive strategy only in males (male:
RR 0.73, 95% CI 0.62 to 0.87; four trials, 4454 participants; fe-
male: RR 0.87, 95%CI 0.65 to 1.16; five trials, 2521 participants;
Analysis 1.12). Late (five-year) follow-up from the FRISC-II trial
also showed that the invasive strategy only significantly benefited
males (RR 0.70, 95% CI 0.59 to 0.86). These subgroup analyses
should be interpreted with caution, and we have explored them
further in the Discussion.
Refractory angina (early, intermediate)
An invasive strategy decreased early refractory angina, based upon
four-month data from RITA-3 (RR 0.47, 95% CI 0.32 to 0.68).
Intermediate refractory angina was significantly decreased using a
routine invasive strategy (RR0.64, 95%CI 0.52 to 0.79; five trials,
8287 participants; Analysis 1.14), although we found significant
heterogeneity at this time point (P < 0.0003, I² statistic = 81%),
which was driven by the ICTUS results. The null effect for this
endpoint in ICTUS was surprising, given that this study recruited
only troponin-positive participants. Indeed, retrospective analy-
sis of troponin-positive participants from the TACTICS-TIMI
18 trial revealed that 94% of troponin-positive participants had
significant angiographic CAD, 79% of whom were revascularised
(PCI or coronary artery bypass grafting (CABG)) during the index
hospitalisation (Dokainish 2005). Hence, the trial participants in
ICTUS would be expected to exhibit high rates of angiographic
CAD and to experience considerable symptomatic improvement
with an invasive strategy. One possible explanation for this dif-
ference in outcomes is that 20% of the participants enrolled in
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ICTUS underwent PCI or CABG prior to randomisation, which
potentially resulted in artificially-improved outcomes in the con-
servative arm as these participants likely had the most to gain from
a routine invasive strategy.
Rehospitalisation for ACS (early, intermediate, late)
The invasive strategy was associated with a significantly decreased
rate of rehospitalisation at the intermediate time point (RR of
0.77, 95% CI 0.63 to 0.94; six trials, 6921 participants; Analysis
1.15), albeit with significant heterogeneity (P = 0.05, I² statistic
= 54%). ICTUS provided late follow-up on rehospitalisation at
three years, at which point no significant benefit persisted (RR
0.79, 95% CI 0.56 to 1.12). This attenuation of earlier signifi-
cance was unsurprising, when we considered the narrowing in the
difference in revascularisation rates between the two strategies in
ICTUS, from a 36% difference at initial hospitalisation between
revascularisation in the routine invasive versus conservative or se-
lective invasive strategies, to only 23% at the termination of fol-
low-up.
Analysis 2: routine use of both stents and
glycoprotein IIb/IIIa receptor antagonists in
revascularisation procedures using PCI
This analysis examined routine use of both stents and glycoprotein
IIb/IIIa receptor antagonists, and included three trials (ICTUS;
LIPSIA-NSTEMI; TACTICS-TIMI 18).
Death: all causes (index, early, intermediate, late)
There was no difference between the treatment strategies at
any of the time points assessed. Data from TACTICS-TIMI
18 and ICTUS at hospitalisation (for index death) and from
TACTICS-TIMI 18 at 30 days (for early death) exhibited a trend
toward increased index death (RR 1.67, 95%CI 0.84 to 3.31; two
trials, 3383 participants; Analysis 1.1) and early death (RR 1.38,
95% CI 0.76 to 2.51; one trial, 2220 participants; Analysis 1.2) in
the invasive arm, but this did not reach statistical significance. In-
termediate death was no different between the treatment strategies
when we combined six-month data from the LIPSIA-NSTEMI
trial and TACTICS-TIMI 18 and 12-month data from ICTUS
(RR 0.92, 95% CI 0.66 to 1.27; three trials, 4020 participants;
Analysis 1.3). In TACTICS-TIMI 18, a routine invasive strategy
did not reduce the risk of death, even in higher-risk participants
with troponin I (TnI) levels greater than 0.1 ng/mL. Late follow-
up from ICTUS (four years) revealed no benefit of a routine in-
vasive strategy on the death endpoint at late follow-up (RR 1.11,
95% CI 0.74 to 1.67; one trial, 1200 participants; Analysis 1.4).
MI (index, early, intermediate, late)
Based on the LIPSIA-NSTEMI, TACTICS-TIMI 18 and ICTUS
data, the routine invasive strategy exhibited no significant differ-
ence inMI rate during the index hospitalisation (RR 0.96, 95%CI
0.51 to 1.83; three trials, 3983 participants; Analysis 1.5). Hence,
there did not appear to be an early hazard to an invasive strat-
egy when glycoprotein IIb/IIIa receptor antagonists were used up-
stream of PCI. EarlyMI was reduced by an invasive strategy, based
on TACTICS-TIMI 18 data at 30 days (RR 0.53, 95% CI 0.35
to 0.79; one trial, 2220 participants; Analysis 1.6). Intermediate
MI was unaffected by an invasive strategy using data for sponta-
neous MI from LIPSIA-NSTEMI, ICTUS and TACTICS-TIMI
18 (RR 0.95, 95% CI 0.56 to 1.60; three trials, 4020 participants;
Analysis 1.7). As already discussed, the TACTICS-TIMI 18 trial
authors did not routinely measure CK-MB post-PCI (Table 2).
Late follow-up from ICTUS (three years) demonstrated no benefit
of an early invasive strategy on the rate of spontaneous MI (RR
1.01, 95% CI 0.66 to 1.55; one trial, 1200 participants; Analysis
1.8).
Death (all causes) or non-fatal MI (index, early,
intermediate, late)
Data for this composite endpoint at index and early (30-day) time
pointswere only available fromTACTICS-TIMI 18.Therewas no
difference between the treatment strategies at index admission (RR
0.77, 95% CI 0.51 to 1.17; one trial, 2220 participants; Analysis
1.9). However, the invasive strategy was associated with significant
early benefit (RR 0.67, 95% CI 0.48 to 0.94; one trial, 2220
participants; Analysis 1.10). Baseline troponin levels were available
from 1826 of 2220 trial participants, and these data formed the
basis for the prespecified subgroup analysis based on TnT levels
greater than (troponin positive) or less than (troponin negative)
0.01 ng/mL. Upon subgroup analysis, the early (30 day) benefit of
a routine invasive strategy only achieved statistical significance in
troponin-positive participants (RR 0.50, 95% CI 0.32 to 0.79).
Troponin-negative participants received no significant benefit at
30-days follow-up (RR 0.95, 95% CI 0.44 to 2.06), although
this CI overlapped with those of troponin-positive participants.
Although the TACTICS-TIMI 18 trial authors prespecified this
subgroup analysis based on troponin, it should nevertheless be
interpreted with caution.
Contrary to the early results, at intermediate (six-month) follow-
up, adoption of a routine invasive strategy yielded no benefit (RR
0.97, 95% CI 0.59 to 1.60; two trials, 2820 participants; Analysis
1.11). The results of this subgroup analysis changed when the
TACTICS-TIMI 18 authors used a different cardiac biomarker.
With subgroup analysis based on a TnI cut-off of 0.1 ng/mL, tro-
ponin-positive participants showed early (30 day) and intermedi-
ate (six month) benefits of an invasive strategy, with a RR of 0.47
(95% CI 0.30 to 0.73) and a RR of 0.67 (95% CI 0.47 to 0.96)
respectively. The TACTICS-TIMI 18 authors prespecified such
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subgroup analysis based on troponin, but should nevertheless be
interpreted with caution. The ICTUS trial suggested no benefit of
a routine invasive strategy at late follow-up regardless of baseline
risk (RR 1.19, 95% CI 0.87 to 1.63; one trial, 1200 participants;
Analysis 1.13); we have explored this further in the Discussion.
Analysis 3: routine stent use in revascularisation
procedures using PCI with selective glycoprotein
IIb/IIIa receptor antagonist use
This analysis included five trials (FRISC-II; Italian Elderly ACS;
the OASIS 5 substudy; RITA-3, VINO).
Death: all causes (index, early, intermediate, late)
There was a non-significant trend towards increased death rate at
index hospitalisation (RR 1.48, 95% CI 0.88 to 2.48; four trials,
4711 participants; Analysis 1.1) and no effect on early death (RR
1.01, 95%CI 0.31 to 3.33; three trials, 2125 participants; Analysis
1.2) in the invasive strategy group. Intermediate death at six to
12 months was not significantly improved by an invasive strategy
(RR 0.85, 95% CI 0.48 to 1.49; five trials, 4895 participants;
Analysis 1.3). However, we noted significant heterogeneity was
noted (P=0.02, I² statistic = 68%). This may have been driven by
the stringent criteria set by the FRISC-II group to define failure
of conservative therapy; and by the large benefit of an invasive
strategy observed in the small VINO study, which randomised
patients with the highest death rates of all five studies (Table 1).
The FRISC-II trial authors undertook subgroup analysis based on
the presence of TnT greater than or less than 0.03 ng/mL and
the presence of ST depression on the admission ECG. Mortality
assessed at one year was not affected by an invasive strategy in this
retrospective analysis, even in the group of participants with both
TnT greater than 0.03 ng/mL and ST depression, although the
numbers of participants may have been too small to detect any
difference. Only FRISC-II and RITA-3 provided follow-up data
for late death at five years, and was not significantly improved by
an invasive strategy (RR 0.87, 95% CI 0.72 to 1.04; two trials,
4267 participants; Analysis 1.4).
MI (index, early, intermediate, late)
Therewere nodifferences in indexMI rates between the two strate-
gies (RR 1.22, 95%CI 0.59 to 2.55; four trials, 4711 participants;
Analysis 1.5), although we found significant heterogeneity (P =
0.06, I² statistic = 59%). The FRISC-II data show a significant
hazard for this endpoint in the routine invasive group (RR 2.22,
95%CI 1.46 to 3.36). Importantly, the four studies in this analysis
did not undertake routine cardiac biomarkers measurements post-
PCI, as the ICTUS and LIPSIA-NSTEMI did, and used clini-
cal symptoms as a diagnostic criterion (Table 2). Significant het-
erogeneity may be due to the distinct VINO definition of MI,
which excluded events within 72 hours of randomisation when
calculating this endpoint. Early MI, based on 30-day VINO and
OASIS 5 data, and four-month RITA-3 data, was not significantly
altered by a routine invasive strategy (RR 0.87, 95% CI 0.52 to
1.44; three trials, 2125 participants; Analysis 1.6). Intermediate
(six-month data from VINO and 12-month data from the Italian
Elderly ACS, FRISC-II, OASIS 5 and RITA-3 studies) and late
MI (five-year FRISC-II and RITA-3 data) significantly decreased
with a routine invasive strategy (RR 0.73, 95% CI 0.60 to 0.89;
five trials, 4895 participants; Analysis 1.7; and RR 0.75, 95% CI
0.63 to 0.90; two trials, 4267 participants; Analysis 1.8, respec-
tively).
Death (all causes) or non-fatal MI (index, early,
intermediate, late)
Death or non-fatal MI at index hospitalisation did not differ be-
tween strategies (RR 1.46, 95% CI 0.75 to 2.86; three trials,
4398 participants; Analysis 1.9). Notably, this contrasts with the
FRISC-II data, from which a significant hazard of the routine in-
vasive strategy was identified for this endpoint (RR 2.07, 95%
CI 1.42 to 3.03). There was no significant benefit with a routine
invasive strategy with respect to early death or non-fatal MI based
on 30-day VINO data (RR 0.30, 95% CI 0.06 to 1.39; one trial,
131 participants; Analysis 1.10). Similarly, there was no difference
between strategies at the intermediate time point (RR 0.91, 95%
CI 0.62 to 1.32; five trials, 4895 participants; Analysis 1.11) with
analysis of data from FRISC-II, RITA-3, OASIS 5 and Italian
ElderlyACS, in addition to VINO.However, drawing on five-year
results from FRISC-II and RITA-3, we noted a significant benefit
for this composite outcome with a routine invasive strategy (RR
0.81, 95% CI 0.72 to 0.92; two trials, 4267 participants; Analysis
1.13).
The FRISC-II data revealed that the intermediate (six to 12-
month) benefit of a routine invasive strategy was only significant
in participants with ST depression at entry, who exhibited a RR
of 0.66 (95% CI 0.50 to 0.88). There was no benefit from a
routine invasive strategy in participants without ST depression,
although such retrospective subgroup analysis should be inter-
preted with caution. Furthermore, FRISC-II troponin subgroup
analysis identified a RR of 0.71 (95% CI 0.53 to 0.93) at 12
months in troponin-positive participants (TnT greater than 0.1
ng/mL), whereas participants with a TnT of less than 0.1 ng/mL
only trended towards benefit with a RR of 0.77 (95% CI 0.53 to
1.11). Again, the CIs of these subgroup analyses overlap and the
results should be regarded with caution. In a separate report, the
FRISC-II trial authors undertook subgroup analysis based on the
presence of TnT greater than versus less than 0.03 ng/mL and the
presence of ST depression on admission ECG. The intermediate
(one-year) death or non-fatal MI endpoint was only significantly
decreased in the group of participants with both TnT greater than
0.03 ng/mL and ST depression greater than 0.1 mV (RR 0.60,
95% CI 0.43 to 0.82). Likewise, the FRISC-II trial authors strat-
18Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the
stent era (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ified participants by FRISC score when they reported late (five-
year) outcomes for this endpoint. We have explored these findings
in the Discussion.
Safety endpoints
Procedure-related MI
Analysis of data from FRISC-II, RITA-3, ICTUS, Italian Elderly
ACS and LIPSIA-NSTEMI showed that the invasive strategy was
associated with an increased risk of procedure-related MI (RR
1.87, 95% CI 1.47 to 2.37; five trials, 6380 participants; Analysis
2.1). We did not identify any heterogeneity, despite the different
diagnostic criteria used for MI: routine measurement of CK-MB
post-PCI in ICTUS and LIPSIA-NSTEMI; and the FRISC-II,
RITA-3 and Italian Elderly ACS studies also included either clin-
ical or ECG criteria, or both, to define MI (Table 2). As already
discussed, the significance of a peri-procedural cardiac biomarker
leak is the subject of considerable debate, but can be modified by
background medications, including use of glycoprotein IIb/IIIa
receptor antagonists (Cutlip 2005). Notably, the increased rate of
procedure-related MI seen in participants subjected to a routine
invasive strategy did not translate into any increased long-term
mortality.
Bleeding
The invasive strategy was associated with an increased risk of
bleeding (RR 1.73, 95% CI 1.30 to 2.31; six trials, 7584 par-
ticipants; Analysis 2.2), although we noted considerable variabil-
ity in bleeding definitions between the included studies that re-
ported this endpoint (FRISC-II; ICTUS, Italian Elderly ACS;
LIPSIA-NSTEMI; OASIS 5; RITA-3). Numerous studies of
people with UA/NSTEMI have identified major bleeding as a
harbinger of a poor ultimate outcome. The ICTUS trial authors
reported major bleeding, which was defined as: fatal bleeding, in-
tracranial bleeding, need for transfusion, a decrease in haemoglo-
bin by 4.8 g/dL, or bleeding causing haemodynamic compromise.
Major bleeding occurred in 3.1% and 1.7% (P = not significant) of
participants randomised to a routine invasive versus conservative
strategy, respectively, during the initial hospitalisation. On four-
year follow-up, mortality was 18.6% in the 29 participants with
major bleeding during initial hospitalisation, versus just 7.5% in
the 1171 participants without an in-hospital major bleed (RR
2.68, 95% CI 1.08 to 6.61).
Stroke
Data from five trials revealed no statistically-significant hazard for
stroke with a routine invasive strategy (RR 0.84, 95% CI 0.38 to
1.86) (ICTUS; Italian Elderly ACS; LIPSIA-NSTEMI; OASIS 5;
TACTICS-TIMI 18).
Contrast reactions
Typically, 1% of participants assigned to an invasive strategy ex-
perienced a contrast allergy. The rate in the conservative strategy
depended on the proportion that underwent subsequent angiog-
raphy, and this depended upon the population risk level.Contrast-
induced renal failure was not reported; however, this outcome can
be modified by the patient’s baseline renal function, hydration sta-
tus and administration of sodium bicarbonate.
Sensitivity analysis
We chose a random-effects model to analyse the results, as it pro-
vides a more conservative estimate of effect size in the presence of a
small number of studies and variable risk levels among randomised
participants. Table 1 highlights important differences between the
included studies, which guided our choice of sensitivity analysis
based on the exclusion of certain studies. We did not subject re-
current angina and rehospitalisation endpoints to sensitivity anal-
ysis, because RR estimates were the most consistent and robust
findings of this meta-analysis and, in general, were not associated
with significant heterogeneity.
Time to angiography
As previously discussed, time to angiography in the invasive arm
could influence outcomes, and optimal timing remains unclear
(Navarese 2013). Indeed, the ISAR-COOL study found that, in
participants with UA/NSTEMI, a ’delayed invasive’ strategy with
angiography three to five days postrandomisation approximately
doubled the risk of death or non-fatal MI over that observed in
participants with an ’early invasive’ strategy in whom angiogra-
phy was performed within six hours of randomisation. The excess
events in the late invasive arm occurred prior to angiography; this
was observed despite background anti-thrombotic therapy which
included aspirin, clopidogrel, tirofiban and heparin. Notably, this
study randomised a high risk population with roughly two thirds
of participants positive for troponin and ST depression on ECG
(ISAR-COOL).Wehave presented the times to angiography in the
’Characteristics of included studies’ table and can be categorised
into an ’immediate invasive’, ’early invasive’ or ’delayed invasive’
strategy. The ICTUS, TACTICS-TIMI 18, VINO and Italian
Elderly ACS studies generally employed angiography within 24
hours of randomisation; whereas in the FRISC-II, OASIS 5 and
RITA-3 studies, angiography was typically delayed for at least two
days.
The increasing interest in timing of invasive strategies has resulted
in more considered comparisons of timing to determine optimal
management. The most recently performed study of the included
clinical trials, the LIPSIA-NSTEMI trial, randomised participants
to immediate, early and selective invasive approaches with median
times from randomisation to angiography of 1.1, 18.6 and 67.2
hours respectively.
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Mortality rates In the conservative arm
We have presented mortality rates in Table 1 as the mortality rate
in the conservative arm divided by the number of years of fol-
low-up. The OASIS 5 substudy, ICTUS, FRISC-II and RITA-3
had mortality rates of 1.1% to 2.8% per year of follow-up, while
TACTICS-TIMI 18 had a rate of 7%, the Italian Elderly ACS
and LIPSIA-NSTEMI trials had rates between 13% and 14%, and
VINO had a rate of 27%. Hence, we analysed the data for OASIS
5, ICTUS, FRISC-II and RITA-3 separately, and the data for
TACTICS-TIMI 18, the Italian Elderly ACS, LIPSIA-NSTEMI
and VINO. When we analysed the high-mortality and low-mor-
tality rate studies separately, the previously-reported findings were
significantly different, which is likely due to the inclusion of the
more recent Italian Elderly ACS and LIPSIA-NSTEMI studies.
These studies, as we will discuss below, included participant co-
horts of high-risk for interventional complications.
Percentage of trial participants with a positive troponin
Findings on subgroup analysis suggest that a positive troponin
may identify high-risk patients likely to experience a particu-
lar benefit with a routine invasive strategy. While the VINO,
ICTUS and LIPSIA-NSTEMI trials only recruited participants
with positive cardiac biomarkers, the percentage of biomarker-
positive participants in the Italian ElderlyACS,OASIS 5 substudy,
FRISC-II, RITA-3 and TACTICS-TIMI 18 studies ranged be-
tween 50% and 80% (Table 1). We analysed the studies that only
randomised biomarker-positive participants separately (ICTUS;
LIPSIA-NSTEMI; VINO) and exhibited a null effect for mor-
tality at all time points. However, this finding should not under-
mine the potential hazards of a routine invasive strategy and the
importance of risk stratification to select high-risk patients who
may experience meaningful benefits that outweigh any potential
harm.
CABG as a mode of revascularization in the invasive arm
We have described the rates of CABG as a mode of revascular-
isation in the invasive arms in Table 1. The OASIS 5 substudy,
ICTUS and TACTICS-TIMI 18 identified rates of approximately
20%, while RITA-3, FRISC-II and VINO had rates of approx-
imately 40%. Consistent with international UA/NSTEMI man-
agement guidelines (Hamm2011; Jneid 2012) and subsequent in-
creasing use of PCI, we observed the lowest CABG rates in the two
studies with the most recent recruitment of participants, Italian
Elderly ACS and LIPSIA-NSTEMI, with rates of 7% and 10% re-
spectively. Performing a sensitivity analysis on the basis of high or
low rates of CABG in the invasive arm used the same data already
utilised in Analyses 2 and 3; hence, the findings were identical to
those already described.
Difference in revascularisation rates between the treatment
arms
We have presented the absolute percentage differences in revascu-
larisation rate between the routine invasive and conservative arms
of each trial in Table 1. The Italian Elderly ACS, FRISC-II and
VINO exhibited higher absolute differences in revascularisation
rate (27% to 39%) relative to the other trials (14% to 23%).When
we pooled the former trials, we noted a non-significant trend to-
wards benefit with a routine invasive strategy at all time points
except the index hospitalisation. Conversely, as the difference be-
tween rates of revascularisation narrows - as is seen for instance in
the LIPSIA-NSTEMI study, which had the highest invasive rate
reported to date amongst participants randomised to a conserva-
tive management strategy (70%) - any benefit derived from a rou-
tine invasive strategy may diminish.
20Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the
stent era (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Routine invasive strategies versus selective invasive strategies (conservative) for UA/ NSTEM I in the stent era
Participant or population: part icipants with UA/ NSTEMI in the stent era
Settings: hospital sett ing
Intervention: rout ine invasive strategies
Comparison: select ive invasive strategies (conservat ive)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Selective invasive strate-
gies (conservative)
Routine invasive strategies
Complications of angiogra-
phy or revascularization
Bleeding
Study population RR 1.73
(1.3 to 2.31)
7584
(6 studies)
⊕⊕⊕©
moderate1
42 per 1000 72 per 1000
(54 to 96)
M oderate risk population
27 per 1000 47 per 1000
(35 to 62)
Complications of angiogra-
phy or revascularization
Procedure-related myocar-
dial infarct ion
Study population RR 1.87
(1.47 to 2.37)
6380
(5 studies)
⊕⊕⊕©
moderate1
30 per 1000 57 per 1000
(45 to 72)
M oderate risk population
29 per 1000 54 per 1000
(43 to 69)
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; UA: unstable angina; NSTEM I: non ST segment myocardial infarct ion.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 Downgraded by one due to possible risk of bias due to lack of blinding.
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D I S C U S S I O N
Summary of findings
Eight randomised controlled trials (RCTs) with a total of 8915
participants (4545 invasive strategies, 4370 conservative strategies)
were eligible for inclusion.
In the all-study analysis, evidence did not show appreciable risk
reductions in all-cause mortality (RR 0.87, 95% CI 0.64 to 1.18;
eight studies, 8915 participants; low quality evidence) and death
or non-fatal myocardial infarction (MI) (RR 0.93, 95% CI 0.71
to 1.2; seven studies, 7715 participants; low quality evidence) with
routine invasive strategies compared to conservative (selective in-
vasive) strategies at six to 12 months follow-up. There was appre-
ciable risk reduction in MI (RR 0.79, 95% CI 0.63 to 1; eight
studies, 8915 participants; moderate quality evidence), refractory
angina (RR 0.64, 95% CI 0.52 to 0.79; five studies, 8287 par-
ticipants; moderate quality evidence) and rehospitalisation (RR
0.77, 95% CI 0.63 to 0.94; six studies, 6921 participants; moder-
ate quality evidence) with routine invasive strategies compared to
conservative (selective invasive) strategies also at six to 12 months
follow-up.
There were increased risks in bleeding (RR 1.73, 95% CI 1.3 to
2.31; six studies, 7584 participants; moderate quality evidence)
and procedure-related MI (RR 1.87, 95% CI 1.47 to 2.37; five
studies, 6380 participants; moderate quality evidence) with rou-
tine invasive strategies compared to conservative (selective inva-
sive) strategies. Low quality evidence was as a result of serious risk
of bias and imprecision in the estimate of effect, while moderate
quality evidence was only due to serious risk of bias.
The risk of index death (during the initial hospitalisation for un-
stable angina and non-ST elevation myocardial infarction (UA/
NSTEMI)) was high when an invasive strategy was adopted from
the outset, with a RR of 1.54 (95% CI 1.02 to 2.34). However,
early death (less than four months), intermediate death (six to 12
months) and late death (four to five years) were not influenced
by management strategy. Though index MI was not significantly
improved with an invasive strategy, we identified significant het-
erogeneity within this analysis, possibly driven by the different
levels of risk, different rates of background medical therapies and
different criteria for ischaemia in the studies included in the analy-
sis. Early MI data from trials that routinely used glycoprotein IIb/
IIIa receptor antagonists revealed a significant benefit of a routine
invasive strategy (RR 0.53, 95% CI 0.35 to 0.79), though in the
all-study combined analysis, this failed to achieve statistical signif-
icance (RR 0.68, 95% CI 0.43 to 1.08).
In comparison to previous versions of this Cochrane review
(Hoenig 2006; Hoenig 2010), the inclusion of OASIS 5, Italian
Elderly ACS and LIPSIA-NSTEMI studies resulted in the loss of
significant benefit in the all-study analysis of a routine invasive ap-
proach at the intermediate MI endpoint (RR 0.79, 95% CI 0.63
to 1.00). However, we observed a significant difference between
strategies at the endpoint with the exclusion of the studies em-
ploying routine glycoprotein IIb/IIIa (RR 0.73, 95% CI 0.60 to
0.89). With a routine invasive strategy, the significant reduction
observed in late MI remained unchanged (RR 0.78, 95% CI 0.67
to 0.92), driven by studies that did not employ routine glycopro-
tein IIb/IIIa strategy (RR 0.75, 95% CI 0.63 to 0.90).
Regarding the composite endpoint of death or non-fatal MI, al-
though a routine invasive approachwas not beneficial at the time of
index hospitalisation, we observed a significant benefit at the early
time point (RR 0.64, 95%CI 0.45 to 0.92). The all-study analysis
of the this endpoint at the intermediate time point lost significance
(RR 0.93, 95% CI 0.71 to 1.20). However, an unchanged benefit
remained significant amongst males (RR 0.73, 95% CI 0.62 to
0.87). Late death or non-fatal MI was unaffected by management
strategy (RR 0.89, 95% CI 0.73 to 1.08). The studies that re-
ported the death or MI endpoint suggest that any benefits of a
routine invasive strategy were significant only in trial participants
with high-risk characteristics, primarily positive troponin or dy-
namic ischaemic electrocardiograph (ECG) changes on admission
or secondary diabetes mellitus, renal insufficiency, reduced EF to
less than 40%, early postinfarction angina, recent percutaneous
coronary intervention (PCI), prior coronary artery bypass grafting
(CABG), or intermediate to high Global Registry of Acute Coro-
nary Events (GRACE) risk score (Hamm 2011). These markers
of risk may have identified populations with higher event rates
and, hence, enhanced the power to detect differences between the
two strategies. The CIs between subgroups overlapped, and these
findings from post-hoc analyses should be interpreted with appro-
priate caution.
We observed a statistically-significant benefit for both refractory
angina and rehospitalisation (RR 0.64, 95% CI 0.52 to 0.79; and
RR 0.77, 95% CI 0.63 to 0.94, respectively) at the intermediate
time point, both driven by the benefit of an invasive strategy in
studies that did not use routine glycoprotein IIb/IIIa inhibitors.
However, the narrowing difference in revascularisation rates be-
tween the two strategies over time reduces the hospitalisation ben-
efit longer term.
Regarding safety endpoints, the invasive strategy was associated
with a 1.9-fold increase in the RR of the variably defined procedu-
rally-related MI endpoint, as well as a 1.8-fold increase in the RR
of bleeding. This bleeding was mainly due to wound site bleeding,
but was difficult to grade due to inter-trial differences in the def-
inition of bleeds and reporting of data. No increase risk of stroke
was noted (RR 0.84, 95% CI 0.38 to 1.86).
Discussion of findings on subgroup analysis
Cardiac troponin status of participants
The baseline cardiac biomarker status of the patient serves as an im-
portant tool for risk stratification, though the idealmarker anddef-
initions remain unclear and have evolved over time with advances
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in technology ( creatine kinase-myocardial band (CK-MB) versus
troponin versus high-sensitivity troponin). The TACTICS-TIMI
18 trial had the prespecified intention of testing the ’troponin hy-
pothesis’: that is, to test whether benefit from an invasive strat-
egy was limited to troponin-positive participants. Data for the
death or non-fatal MI endpoint from TACTICS-TIMI 18 and
FRISC-II suggest that only high-risk participants with a positive
troponin benefited from a routine invasive strategy with respect to
this endpoint. However, the CI for this subgroup analysis showed
overlap with that of troponin-negative participants. The Italian
Elderly ACS reinforced the importance of baseline troponin status
on treatment effect, and identified a significant reduction in the
primary endpoint (composite of death, MI, disabling stroke and
repeat hospital stay for cardiovascular causes or severe bleeding
within one year) amongst participants with an elevated troponin
on admission (hazard ratio (HR) 0.43, 95% CI 0.23 to 0.80) but
not in those with normal troponin (HR 1.67, 95% CI 0.75 to
3.70). Data from VINO, which only included participants with
clinical symptoms, ECG changes and positive cardiac biomarkers,
revealed a significant 72% risk ratio reduction in this endpoint
at six months. However, the ICTUS trial, which also exclusively
enrolled troponin-positive participants, had an unexpectedly low
baseline mortality rate relative to the other included studies (Table
1). This may be partly due to optimal medical therapy in the
ICTUS trial versus other included trials wherein, in both trial
arms, early use of clopidogrel and intensive lipid-lowering therapy
was recommended to treating clinicians. Alternatively, this may be
a statistical outlier given the large CIs for mortality in these stud-
ies. Disparate event rates in participants with positive troponin
highlights the importance of global risk stratification as opposed
to using cardiac biomarkers as a single risk index. Indeed, in a ret-
rospective analysis of the FRISC-II data (Diderholm 2002), death
or non-fatal MI experienced a significant 40% risk ratio reduction
only in participants with both troponin T (TnT) greater than 0.03
ng/mL and ST depression on admission ECG. Hence, although
ICTUS participants all had a TnT of greater than 0.03 ng/mL,
this sole criterion did not necessarily identify a risk level that might
benefit from invasive treatment. The risk associated with troponin
elevation has been shown to be a continuous variable and therefore
classification as a dichotomous variable may dilute its predictive
power.
Though some have argued that the prognostic value of troponin
is greater than that of CK-MB (Montalescot 2009; Saenger 2008;
Thompson 1979), troponin may be overly sensitive for the de-
tection of re-infarction and only elevated CK-MB has been cor-
related with evidence of myocardial necrosis (Lim 2011). Retro-
spective analysis performed by the TACTICS-TIMI 18 trial au-
thors highlights the limitations of purely using a positive troponin
to predict event rates. Analysis of the invasive arm revealed that
6% of the participants with a positive troponin test did not have
significant angiographic coronary artery disease (CAD), defined
as greater than 50% stenosis of any coronary artery (Dokainish
2005). At six months, these participants had a 3.1% rate of death
or re-infarction, compared to 0% among those with a negative
troponin and no angiographic CAD. As would be expected, tro-
ponin-positive participants with angiographic CAD had a high
rate of death or re-infarction (8.6%) at six months. Interestingly,
participants with angiographic CAD who had a negative troponin
had a 5.8% rate of death or re-infarction at six months, which is
clearly higher than that for troponin-positive participants without
angiographic CAD. Hence, troponin alone cannot be used to risk
stratify patients. Moreover, this analysis highlights the limitations
of angiography in the assessment of plaque burden. In general in
unstable angina studies, positive troponin status has been shown
to correlate with complex coronary lesions on angiography and re-
duced coronary flow (Benamer 1999; Heeschen 1999a; Hochman
1999), but should not be used alone to identify those at high-risk.
However, absolute values of troponin exhibit a linear relationship
with subsequent risk of coronary events. Troponin positivity has
also been shown to predict benefit from glycoprotein IIb/IIIa re-
ceptor antagonists (Hamm 1999; Heeschen 1999b), an early in-
vasive strategy in the elderly (Italian Elderly ACS), and remains a
critical element of risk stratification.
ST depression on admission
As previously mentioned, ECG changes on admission forebode a
worse prognosis in UA/NSTEMI patients. Indeed, data from the
TIMI III Registry shows that patients with ST depression on ad-
mission ECG have a 2.5-fold increased risk of death or MI within
one year (Cannon 1997). In the ICTUS and TACTICS-TIMI
18 trials, ST depression was an independent predictor of failure
of medical therapy with the conservative strategy (Sabatine 2006;
Windhausen 2007b). As discussed above, on post-hoc analysis of
FRISC-II data, the benefit of a routine invasive strategy on the
endpoint of death or non-fatal MI only achieved statistical sig-
nificance in participants with ST depression on admission ECG.
In FRISC-II and the TIMI III Registry, the prevalence rates for
triple-vessel and left main artery disease were approximately 50%
and 66%, respectively, in participants who had ST depression on
admission ECG. Similarly, the TACTICS-TIMI 18 study identi-
fied an odds ratio for three-vessel disease of 1.79 in participants
with ST deviation of 0.05 to 0.09 mV, and an odds ratio of 1.91 in
those with a ST deviation greater than 0.10 mV versus those with
a ST deviation less than 0.05 mV. Hence, the ECG can be used
as a tool to identify patients who are likely to benefit from revas-
cularisation. Analysis of the FRISC-II data demonstrated that ST
depression was still a predictor of benefit from an invasive strat-
egy, even after baseline differences were accounted for (Holmvang
2003). Furthermore, this analysis also suggested that the benefits
of a routine invasive strategy were further amplified with increas-
ing amplitude of ST depression in an increasing number of ECG
leads.
Data fromTACTICS-TIMI 18 confirms the utility of ST segment
changes in identifying a higher-risk population that may benefit
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from an invasive strategy. Unfortunately, we could not obtain data
for the composite endpoint of death or non-fatal MI, but the study
includes data for the endpoint of death or non-fatal MI or rehos-
pitalisation for ACS. Using this endpoint, the RR was 0.62 (95%
CI 0.53 to 0.74) in participants with baseline ST changes, while
no effect was observed in those without such changes. The ICTUS
data show a trend towards decreased rates of (spontaneous) MI at
one year in those randomised to a routine invasive strategy, with a
risk ratio of 0.74 (95% CI 0.40 to 1.38). However, the events were
few andCIswere wide. In light of the potential implications of ST-
depression on treatment effect, we have provided the percentages
of trial participants with ST depression on index ECG in Table 1,
with the highest rates of 62% reported in the LIPSIA-NSTEMI
study. In general the studies eligible for analysis did not provide
data for subgroup analysis of ST depression and troponin status.
While subgroup analyses may identify populations with increased
risk, and hence provide increased power to detect statistical signif-
icance, such post-hoc analyses should be interpreted with caution.
Gender
Disparate outcomes of a routine invasive strategy based on gender
has been a source of controversy. The all-study (Analysis 1) gen-
der subanalysis for intermediate death or non-fatal MI revealed a
benefit of routine invasive strategy confined to males. However,
the number of women in the studies was lower than the number
of men, and the decreased power to detect any advantage of rou-
tine invasive strategy is highlighted by the comparatively wide CIs.
TACTICS-TIMI 18 identified no significant interaction between
gender and outcomes based on treatment strategy. Conversely, the
FRISC-II and RITA-3 trials found significant benefit of a routine
invasive strategy for death or MI amongst men, but not women.
Supporting this, the OASIS 5 substudy, which randomly assigned
184 women to a routine or selective invasive strategy, identified
significantly more deaths after one year (HR 9.01, 95%CI 1.11 to
72.90) and higher rates of major bleeding at 30 days (HR 11.45,
95% CI 1.43 to 91.96) with a routine invasive strategy.
Confounding comparison and interpretation of these results,
women had less severe CAD across the studies analysed, and were
less likely to have an elevated troponin level than men (Clayton
2004; Glaser 2002; Lagerqvist 2001). Moreover, in FRISC-II and
RITA-3, women in the conservative arm had a better progno-
sis than men in the conservative arm. A retrospective analysis of
TACTICS-TIMI 18 data suggests that, after adjusting for differ-
ences in baseline characteristics, the benefits of an early invasive
strategy in women were the same as those seen in men (Glaser
2002). In contrast, similar analyses undertaken by FRISC-II and
RITA-3 trial authors failed to demonstrate any benefit of an in-
vasive strategy in women, even after they adjusted for baseline
characteristics. The RITA-3 analysis suggested that women had
better outcomes than men when managed conservatively and did
not benefit from an invasive strategy, even when those with high-
risk features were analysed separately (Clayton 2004). Women in
TACTICS-TIMI 18 and RITA-3 were less likely than men to un-
dergo CABG, even when trials adjusted for the presence of three-
vessel or left anterior descending artery disease (Clayton 2004;
Glaser 2002).Notably in FRISC-II, where the rates of CABGwere
similar in both men and women, the one-year mortality rate in
participants undergoing CABG was 9.9% in women versus just
1.2% in men (Lagerqvist 2001). Higher operative CABG mortal-
ity has been observed in women enrolled in observational studies
and this discrepancy could not be accounted for by age, co-mor-
bidities or smaller body surface area (Blankstein 2005). These ret-
rospective analyses should be interpretedwith appropriate caution.
They highlight the importance of further research to determine
the optimal treatment strategy in women, and the importance of
risk stratification, especially in women who are less likely to have
angiographic CAD when compared to their male counterparts,
and requisite caution extrapolating results from men to women.
Other subgroups
We have discussed other subgroups of interest that we did not
prespecify in our protocol, Hoenig 2004, as a narrative review in
this section.
Elderly
The elderly (aged over 65 years) comprise the majority of hospital
admissions for UA/NSTEMI. Given the higher risk of recurrent
events in this group compared to counterparts who are younger,
increased absolute risk may translate into a greater absolute risk
reduction with improved understanding of the relative benefits of
invasive versus conservative management (Alexander 2007). De-
spite this, there is a deficit of knowledge regarding themanagement
of elderly patients, since the included studies in this Cochrane re-
view generally excluded participants over 75 years of age.
The Italian Elderly ACS was the only RCT to specifically compare
treatment strategies in elderly participants with non-ST-elevation
ACS. Here, we did not identify any statistical difference between
early aggressive and initially-conservative groups for the primary
endpoint of composite death,MI, disabling stroke and repeat hos-
pital stay for cardiovascular or bleeding causes (HR 0.80, 95% CI
0.53 to 1.19) or for mortality (HR 0.87; 95% CI 0.49 to 1.56),
MI (HR 0.67, 95%CI 0.33 to 1.36) or repeat hospitalisation (HR
0.81, 95%CI 0.45 to 1.46) when examined alone. However, strat-
ification of participants dependent on baseline troponin revealed a
significant reduction in the primary endpoint amongst troponin-
positive (HR 0.43, 95%CI 0.23 to 0.80) versus troponin-negative
participants (HR 1.67, 95%CI 0.75 to 3.70; P = 0.03). Implicit in
this is the lost advantage of an early invasive strategy in troponin-
negative elderly, who can be safely managed conservatively. These
findings are supported by the collaborative analysis of individual
data from the FRISC II-ICTUS-RITA 3 (FIR) trials (Damman
2012), where a 29% reduction in cardiovascular death or MI was
reportedwith a routine invasive strategy in participant greater than
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or equal to 75 years old, with sustained benefit still demonstrated
at long-term follow-up.
A retrospective analysis of the TACTICS-TIMI 18 trial showed
that those over 65 years of age were more likely to have high-risk
features, such as elevated troponin levels, ST-deviation, diabetes
and congestive heart failure (Bach 2004). Indeed, 90% of those
over 65 years old had intermediate to high-risk TIMI scores (score
greater than or equal to three), versus just 63% of those under 65
years of age. Overall, the routine invasive strategy reduced early
and intermediate death or MI when compared to conservative
management amongst those over 65 years of age, with risk ratios of
0.58 (95% CI 0.37 to 0.92) and 0.64 (95% CI 0.45 to 0.93), re-
spectively. The invasive strategy did not significantly benefit those
under 65 years old, which suggests that benefit increases with age,
though the CIs were wide and overlapped. However, major bleed-
ing was higher with the invasive strategy in those over 65 (RR
1.74, 95% CI 1.12 to 2.70), while no such hazard was observed
in those under 65 years of age.
Reassuringly, in both the Italian Elderly ACS and the retrospective
analysis of the TACTICS-TIMI 18 trial, stroke was not increased
with an invasive strategy in the elderly, and in fact demonstrated a
trend towards decreased events with the routine invasive strategy
adopted in TACTICS-TIMI 18. The results of this type of analysis
are unsurprising, given that the elderly are at increased risk of
events. Therefore, retrospective analysis should have greater power
to identify benefits of an intervention with absolute event rates.
The FRISC-II trial authors also published risk ratio estimates
for participants based on age; and while the risk estimate was
only significant in those over 65 years old, the risk estimate for
those under 65 years of age was similar and the CIs overlapped
(Lagerqvist 2006). However, the results fromTACTICS-TIMI 18
and FRISC-II differ from older excluded studies such as TIMI-3b,
which showed a significant hazard of intervention in younger trial
participants. This point again reinforces the reasoning behind only
including studies that were undertaken in the stent era, since older
studies are irrelevant to contemporary practice.
The 2012 American College of Cardiology Foundation/Ameri-
can Heart Associate (ACCF/AHA) focused update, Jneid 2012,
and the 2011 European Society of Cardiology (ESC) guidelines,
Hamm 2011, on the management of UA/NSTEMI endorse an
early invasive strategy (Level B evidence) for elderly patients, de-
spite increased early procedural risks. Moreover, since elderly pa-
tients recruited into clinical trials generally have fewer cardiovascu-
lar risk factors, fewer co-morbidities, and better haemodynamics
and renal function than community-dwelling elderly, event rates
and benefits from a routine invasive strategy might be even greater
in the ’real world’. Registry data support the use of the routine
invasive strategy in the elderly, and there is no stroke hazard as
a consequence of routine intervention reported in contemporary
registries (Bauer 2007).
However, in the real world, acute coronary care for the elderly is
provided within the context of the health and co-morbid status of
the patient. These factors also need to be considered for therapeu-
tic decision-making. Despite the lack of any statistically-signifi-
cant benefit with an invasive strategy in younger age groups, this
is not to say that younger patients with high-risk features would
not benefit from a routine invasive approach. Age is included in
the TIMI risk score, which integrates several prognostic variables
readily available from the clinical history and first-line investiga-
tions (Antman 2000). Similarly, retrospective analyses from the
included studies have suggested that diabetes, peripheral arterial
disease and a history of previous coronary artery bypass grafting are
co-morbid conditions associated with an increased risk of events
and, hence, the potential for enhanced benefit from an early inva-
sive strategy, as well as a more favourable risk-benefit ratio (Januzzi
2005; Kugelmass 2006; Norhammar 2004). However, as with age,
there is co-variation with other indicators of high-risk. Conse-
quently, while retrospective analyses that focus on a single indi-
cator of higher risk are interesting, a universal and easily-applied
method of risk stratification that can be utilised by the practicing
physician would be of greater interest.
Diabetics
The relative benefit of adopting a routine invasive strategy has
been a contentious issue amongst people with diabetes, who have
both an increased risk of recurrent cardiovascular events and an
increased risk of intervention due to co-morbid conditions. A col-
laborativemeta-analysis of RCTs,which incorporated 9904 partic-
ipants, compared conservative verse invasive treatment strategies
between diabetic and non-diabetic patients (O’Donoghue 2012).
Although an invasive strategy yielded similar reductions in diabetic
and non-diabetic participants in overall cardiovascular events, the
reduction in recurrent non-fatal MI was greater in diabetic par-
ticipants. The data presented by O’Donoghue 2012 support the
2012 ACCF/AHA focused update (Jneid 2012; Level B evidence)
and the 2011 ESC guidelines (Hamm 2011; Level A evidence),
which recommend use of an invasive strategy for people with di-
abetes who present with UA/NSTEMI.
The importance of global risk stratification
As the above discussion highlights, and as subgroup analyses have
illustrated, risk stratification is an integral component of manag-
ing patients with UA/NSTEMI. The goal of risk stratification is
to identify patients with a high likelihood of complicated CAD
who are at increased risk of recurrent coronary events or premature
death, and to offer such patients the benefits of revascularisation.
However, the clinical distinction between UA and NSTEMI does
not adequately stratify high-risk patients (Zaacks 1999). Con-
sequently, the current 2012 ACCF/AHA focused update, Jneid
2012, and the 2011 ESC guidelines, Hamm 2011, recommend
using several parameters for risk stratification; as occurs with the
application of risk scoring tools, for example the TIMI risk score
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(Antman 2000). To underscore this point, in a post-hoc analy-
sis of the FRISC-II data, participants with troponin T of greater
than 0.03 ng/mL and ST depression experienced a statistically-
significant benefit with a routine invasive strategy, whereas partic-
ipants with only one of these variables did not (Diderholm 2002).
Only TACTICS-TIMI 18 undertook subgroup analyses based on
TIMI risk scores, and stratified the participants into three cate-
gories based on their TIMI risk score: low-, intermediate- or high-
risk. In this study, only intermediate- and high-risk participants
benefited from the invasive strategy, regarding the primary com-
posite endpoint of death or non-fatal MI or rehospitalisation for
ACS. Unfortunately, data for the composite endpoint of death or
non-fatal MI were unavailable and therefore we could not incor-
porate them into this Cochrane review.
The TIMI score was extracted from the unfractionated heparin
arm of the TIMI 11B trial (TIMI 11B 1999). It was validated
in the enoxaparin arm of TIMI 11B and in both arms of the
ESSENCE 1997 trial. The risk score was shown to be a valid pre-
dictor of the composite endpoint encompassing all-cause mortal-
ity, MI and urgent revascularisation within 14 days of randomisa-
tion. Importantly, the TIMI score also predicted each of the com-
ponents of this composite endpoint (Antman 2000). The TIMI
risk score was subsequently validated in the TIMI III Registryof
unselected UA/NSTEMI patients and was shown to predict the
endpoint of death, MI or recurrent ischaemia and the compo-
nents of the composite outcome at both six weeks and one year
(Scirica 2002). Further, the TIMI risk score was validated for the
death, MI or recurrent ischaemia composite endpoint for up to
six months in the PRISM-PLUS Trial; and it was shown to pre-
dict benefit from tirofiban, even in participants with a negative
CK-MB (Morrow 2002). Hence, this versatile risk score is able to
identify patients with high event rates who may also benefit from
an invasive strategy. Intuitively, one would expect that patients
with higher TIMI scores, and therefore a higher risk for mortality
and recurrent events, have more extensive CAD on angiography.
This has been confirmed in a retrospective analysis of patients
with UA/NSTEMI (Garcia 2004). The PRISM-PLUS Trial au-
thors also confirmed these findings by a retrospective analysis, and
found the TIMI score to correlate with impaired epicardial artery
blood flow and the presence of visible thrombus on angiography
(Mega 2005). Although there are other published risk scores for
UA/NSTEMI (de Araújo Gonçalves 2005), the TIMI risk score
is perhaps the most widely used. In addition, the low event rates
in ICTUS, which exclusively enrolled troponin-positive partici-
pants, highlight the importance of considering multiple variables
in risk stratification. Indeed, on five-year follow-up by the RITA-3
trial authors, nine factors other than treatment group emerged
as multi-variate predictors of death or non-fatal MI (Fox 2005).
When the logistic coefficients for the risk factors were added and
the study population divided into quartiles based upon risk score,
participants in the highest quartile of risk score experienced sub-
stantially greater benefit from an invasive strategy. Similarly, the
FRISC-II trial authors developed a FRISC score, ranging from
zero to seven, with one point alloted for each of seven factors:
age of over 70 years, male sex, diabetes, previous MI, ST depres-
sion, increased troponin, and increased interleukin-6 or C-reactive
protein (Lagerqvist 2005). Having a medium to high-risk (score
of three to seven) predicted benefit from an early invasive strat-
egy, with risk ratios of 0.64 (95% CI 0.51 to 0.80) at two years
and 0.75 (95% CI 0.64 to 0.89) at five years for the composite
endpoint of death or non-fatal MI (FRISC-II). Low-risk patients
(score zero to two) did not benefit and had a trend towards harm
for the composite endpoint of death or non-fatal MI, with a RR
of 1.62 (95% CI 0.71 to 3.69) at two years and 1.26 (95% CI
0.66 to 2.40) at five years (FRISC-II). In contrast, the ICTUS
trial authors confirmed the prognostic utility of the FRISC score,
but were unable to predict benefit from an early invasive strategy
in this trial; even participants with the highest FRISC scores (five
to seven) derived no benefit from an early invasive approach (RR
1.30, 95% CI 0.69 to 2.47), in terms of the late death or MI
endpoint.
Current ’real world’ event rates in patients with UA/NSTEMI
compared to rates observed in the included trials
The largest multinational registry, theGRACE registry, which col-
lects data from 30 countries, has reported mortality rates in pa-
tients hospitalised with various forms of acute coronary syndrome
(ACS). Entry criteria for this registry include a history of chest pain
and one of the following: ischaemic ECG changes, increased car-
diac biomarkers or a documented history of CAD. The in-hospital
mortality rates for patients recruited between 1999 and 2002 were
5.9% for patients with NSTEMI and 2.7% for patients with un-
stable angina. Also, the six-month post-discharge mortality rates
were 6.2% and 3.6% for NSTEMI and unstable angina, respec-
tively (Goldberg 2004). Furthermore, rehospitalisation rates six
months post-discharge were roughly 20%. Another report from
the GRACE registry, which included patients recruited between
1999 and 2003, reported the six-month post-discharge mortality
rates as 11.6% for NSTEMI and 6.8% for unstable angina (Van
de Werf 2005). Clearly, the mortality rates from this real-world
registry are higher than those observed in the studies included in
our meta-analysis, as shown in Table 1. However, these patients
did not receive optimal medical management in that only approx-
imately 50% of NSTEMI patients received ACE inhibitors, hep-
arin or statins (Goldberg 2004). While over 90% of patients re-
ceived aspirin and over 80% received beta blockers, it is unlikely
that many would have received clopidogrel as the patients studied
were entered into the registry prior to publication of the CURE
trial (CURE 2001); that is, before use of clopidogrel for UA/
NSTEMI became accepted as standard therapy. Similarly, partic-
ipants enrolled in the UA/NSTEMI trials received higher rates
of medical therapy than participants enrolled in the CRUSADE
registry (Kandzari 2005). However, the discrepancy in mortal-
ity rates between the participants in the included studies of this
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Cochrane review and registry-reported mortality rates is arguably
too high to be explained by advances in the medical management
of UA/NSTEMI alone. Another explanation may be that selec-
tion and recruitment protocols may bias trials towards enrolling
participants with a risk lower than that seen in unselected partici-
pants entered into registries. While analysis of available data sug-
gests that high-risk patients may benefit from an invasive strategy,
this absolute benefit is likely to narrow as early medical therapies
and risk stratification procedures for UA/NSTEMI improve, com-
bined with the appropriate use of deferred coronary angiography
and revascularisation. Novel medical therapies, such as prasugrel
(TRITON-TIMI 38) and ticagrelor (PLATO) instead of clopi-
dogrel, continue to decrease absolute event rates in patients with
UA/NSTEMI. Consequently, future trials of invasive versus con-
servative management for UA/NSETMI will be required as novel
medical therapies are adopted. It is likely that only progressively
higher-risk patients will continue to benefit from routine invasive
intervention in the future. A report from the GRACE registry has
shown that increasing use of evidence-based therapies has trans-
lated into reduced event rates over time (Fox 2007b). However,
the lack of benefit observed for several endpoints in this review
may be due to lower-risk patients having been selected for trial
enrolment.
The general paucity of enrolment of participants with cardiogenic
shock or an advanced Killip class in the included studies may
mean that the results of this systematic review are not applicable to
this high-risk subset. Advanced Killip class has been identified as
an independent predictor of mortality in patients with NSTEMI
(Khot 2003), while Killip class and congestive heart failure (de-
velopment of or history of ) were shown to predict death and the
composite of death or MI in the GRACE registry (Fox 2006). In-
deed, the current ACCF/AHA guidelines for UA/NSTEMI rec-
ommend using signs of heart failure as markers of increased risk
(Jneid 2012).However,most of the included studies did not report
Killip class, EF or brain natriuretic peptides among their baseline
characteristics; and the event rates in the included studies indicate
that participants with cardiogenic shock were excluded. Two ex-
ceptions to this are the FRISC-II trial, in which 13% of partici-
pants were reported to have an EF of less than 45% at baseline,
and the VINO trial, in which 53% of the sample were reported
to be Killip class of II or III at baseline. This high percentage of
participants with pulmonary oedema in VINO may explain why
this trial had the highest standardised mortality rates of the in-
cluded studies (Table 1); and, while being a small trial, identi-
fied a robust benefit for routine invasive strategy. Observational
data have revealed that Killip class II and III patients enjoyed a
significant mortality benefit (at 30 days and six months) from
an invasive strategy, while Killip class I patients did not benefit
(Rott 2001). The SHOCK 1999 trial (302 participants), which
recruited STEMIpatients with cardiogenic shock, uncovered a sig-
nificant mortality benefit for a routine invasive versus conservative
strategy at six months, with mortality rates of 50.3% and 63.1%
(P = 0.027), respectively (SHOCK 1999). These are consistent
with observations from the GRACE registry (Dauerman 2002).
Similarly, elevated N-terminal pro-brain natriuretic peptide (NT-
proBNP) has been shown to predict a poor prognosis in patients
with UA/NSTEMI, independently of age, Killip class or left ven-
tricular EF (Jernberg 2004). In a retrospective subgroup analy-
ses from FRISC-II (2017 participants), NT-proBNP measured at
median of 39 hours after symptom presentation correlated (corre-
lation coefficient, r) with TnT (r = 0.53, P < 0.001), interleukin-
6 (r = 0.29, P < 0.001) and the severity of coronary disease on
angiography (Jernberg 2003). A relationship between higher brain
natriuretic peptide (BNP) and more severe angiographic coronary
disease was also evident in a small retrospective analysis from the
TACTICS-TIMI 18 trial, which also demonstrated higher BNP
to be associated with higher TIMI frame counts, consistent with
reduced myocardial perfusion (Sadanandan 2004). In FRISC-II,
NT-proBNP predicted two-year mortality independently of TnT,
interleukin-6 and left ventricular EF, but failed to predict the in-
cidence of MI. Importantly, this retrospective subgroup analysis
from the FRISC-II trial authors suggested that the early invasive
strategy only improved two-year mortality in participants within
the highest tertile for NT-proBNP (greater than 906 ng/L for
men, greater than 1345 ng/L for women) and with an interleukin-
6 concentration greater than 5 ng/mL (absolute risk reduction of
7.3%; RR 0.46, 95%CI 0.21 to 1.00). Such retrospective analyses
are hypothesis-generating and by no means definitive. A similar
analysis from TACTICS-TIMI 18 (1676 participants) measured
BNP instead of NT-proBNP, and dichotomised participants at
a BNP of greater than 80 ng/L. The analysis found that partici-
pants with an elevated BNP exhibited greater seven-day and six-
month mortality (2.5% versus 0.7%, P < 0.01; and 8.4% versus
1.8%, P < 0.01 respectively). However, BNP was not shown to
predict any benefit from invasive management (Morrow 2003).
This may be due to the relatively short follow-up performed in the
TACTICS-TIMI 18 study, which was only six months (Table 1).
The ICTUS trial authors also examined the prognostic influence
of NT-proBNP measured a median of 13 hours after presenta-
tion in a 1141-participant subgroup extracted from the main trial
(Windhausen 2007a). In the highest quartile (greater than 1170
ng/L for men, greater than 2150 ng/L for women), one-year mor-
tality was 7.3%, compared to just 1.1% among participants in the
lower three quartiles. However, as with the retrospective analyses
from the FRISC-II and TACTICS-TIMI 18 trials, NT-proBNP
failed to predict MI and, in contrast to FRISC-II, elevated NT-
proBNP did not predict any benefit from an early invasive strat-
egy in the ICTUS cohort (Windhausen 2007a). Hence, the role
of natriuretic peptides and the assessment of patients for clinical
features of congestive heart failure in UA/NSTEMI need to be
further elucidated. In the interim, patients with features of con-
gestive heart failure need to be considered at high-risk for death
and managed aggressively.
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The GRACE investigators identified predictors of a poor prog-
nosis that were derived from and validated in cohorts enrolled
in GRACE from 1999 to 2002 and 2002 to 2003, respectively
(Eagle 2004). The investigators identified nine variables - older
age, history of MI, history of heart failure, increased heart rate,
lower systolic blood pressure, elevated serum creatinine, elevated
cardiac biomarkers, STdepression and not undergoing PCI - as in-
dependent predictors of increased six-month mortality across the
ACS spectrum. Of particular note is that the GRACE risk score
incorporates renal function, which is an important, practical risk
prognosticator in UA/NSTEMI that was not considered when the
TIMI risk score was derived (Antman 2000). In a retrospective
subgroup analysis of the FRISC-II trial, creatinine clearance was
estimated from serum creatinine using the Cockcroft-Gault for-
mula (Johnston 2006). In conservatively-managed patients, the
rates of death or MI for creatinine clearances of less than 69 mL/
min, 69 to 90 mL/min and greater than 90 mL/min were 22.4%,
14.6% and 11.6%, respectively. The corresponding event rates in
the invasive group were 14.6% (P < 0.01 versus conservative treat-
ment), 9.9% (P = 0.048) and 11.2% (P = not significant), respec-
tively. Indeed, there was a significant interaction between treat-
ment strategy and outcomes in patients with a creatinine clearance
of less than 90 mL/min. These data are indeed sobering, since
patients with renal dysfunction are often denied aggressive ther-
apy in the real world, possibly because of clinician concerns about
bleeding risk and a poor prognosis regardless of therapy. These
data are particularly relevant to clinicians practicing in countries
where an estimate of glomerular filtration rate is mandatory on
adult electrolyte panels, as is standard in the USA and Australia.
Hence, risk stratification is an integral part of the management of
patients with UA/NSTEMI and needs to be considered carefully
in future prospective RCTs on the topic. Moreover, the roles of
estimated glomerular filtration rate and NT-proBNP as risk prog-
nosticators over and above established markers such as the TIMI
risk score need to be further evaluated.
Current ’real world’ management of patients with
UA/NSTEMI, emphasising the relationship between patient
risk and subsequent management
Despite the extensive literature that exists on risk stratification,
real-world data from the GRACE registry has shown that high-
risk patients are no more likely to receive enoxaparin or glycopro-
tein IIb/IIIa receptor antagonists or to undergo catheterisation and
PCI than low-risk patients (Oliveira 2007). In a different analy-
sis from the GRACE registry that only included participants re-
cruited with direct access to a catheterisation laboratory, there was
an inverse relationship between the level of patient risk (measured
as a GRACE risk score) and the frequency of angiography and
PCI (Fox 2007a; Ranasinghe 2011). Indeed, the rates of cardiac
catheterisation in low-, medium- and high-risk patients with UA/
NSTEMI were 72%, 68% and 51%, respectively, while the rates
of PCI were 40%, 35% and 25%, respectively (Fox 2007a). In ad-
dition, thienopyridines and glycoprotein IIb/IIIa receptor antago-
nists weremore commonly used in low-risk patients thanmedium-
or high-risk patients with similar findings in a Canadian registry
(Yan 2007). Likewise, diabetics with UA/NSTEMI, despite their
higher risk, are not treated more aggressively than non-diabetics
(Franklin 2004). The reasons for the discrepancy between patient
risk and treatment have been unclear, but recent data from a Cana-
dian registry suggest that the most common reason for under-uti-
lization of an invasive strategy in high-risk patients is the treating
physician’s underestimation of patient risk (Lee 2008). In this re-
gard, a focused initiative to educate physicians on risk stratifica-
tion could enhance quality of care in patients with UA/NSTEMI.
It is also important to recognise that access and distance to car-
diac catheterisation services are established predictors of treatment
strategy.
Quality of life endpoints
Although not an initial outcome of this systematic review, this
section provides a narrative discussion of health-related quality of
life (HRQOL) outcomes. Four studies (Eisenberg 2005; RITA-3;
FRISC-II; TACTICS-TIMI 18) specifically compared HRQOL
and functional status following invasive versus non-invasive man-
agement forNSTEMI.One trial (Eisenberg 2005) selected change
in QOL as a primary endpoint, and the other three (RITA-3;
FRISC-II; TACTICS-TIMI 18) had HRQOL measures as sec-
ondary endpoints. In the primary endpoint trial, which included
only 88 participants (Eisenberg 2005), there was no difference be-
tween the two groups at 12 months in terms of the level of peak
exercise reached on an endurance exercise treadmill (7.8 versus 6.7
metabolic equivalents). Functional status was improved in the in-
vasive group (Duke Activity Status Index scores 4.3 versus −3.5,
P = 0.04), as was angina-specific quality of life, assessed using the
Seattle Angina Questionnaire measure of anginal stability (21.6
versus −5.3, P = 0.020), anginal frequency (22.9 versus 2.3, P =
0.02) and treatment satisfaction (11.2 versus −10.3, P = 0.02).
In the RITA-3 trial, Kim 2005 assessedHRQOLwas assessed with
the Short Form-36 (SF-36), Seattle Angina Questionnaire (SAQ),
EuroQOLVisual Analogue Scale (EQ-VAS) and EuroQOL 5-Di-
mensional Classification (EQ-5D) scale at baseline, four months
and one year follow-up. Mean changes from baseline EQ-VAS
scores were better for the invasive versus non-invasive strategy at
four months (treatment difference of 3.0, P < 0.001) and one year
(2.3, P < 0.01). The EQ-5D utility scores were also higher in the
invasive group at four months (treatment difference 0.036, P <
0.01) but not at one year (0.016, P = 0.20). For the SF-36, the
invasive strategy group scored significantly better at four months
for physical function, physical role function, emotional role func-
tion, social function, vitality and general health. The SAQ scores
for exertional capacity, anginal stability and frequency, treatment
satisfaction and disease perception were significantly better for the
invasive strategy group at both four months and one year, though
attenuated at the last follow-up. The study authors concluded that
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improvements in HRQOL associated with the invasive strategy
were most likely due to improved in anginal symptoms.
In theFRISC-II trial, Janzon 2004 measured HRQOL was mea-
sured using the generic Medical Outcomes Study SF-36 and the
disease-specific Angina Pectoris Quality of Life Questionnaire
(APQLQ) at baseline and three, six and 12 months follow-up.
The invasively-treated group reported a significantly better qual-
ity of life in all eight scales and both component scores (physi-
cal and mental) of the SF-36 at three and six months of follow-
up (P < 0.01) relative to the non-invasively treated group. These
differences remained at 12 months follow-up, with significance in
seven of the scales and in the physical component score. The in-
vasive group scored significantly higher on all five subscales of the
APQLQ scores at three months (P < 0.01), and on four subscales
at six months (P < 0.05), but only on one subscale at one year.
Regarding theTACTICS-TIMI 18 trial,Weintraub 1999 planned
to assess health status using somemeasure of utility in order to per-
form cost-effectiveness evaluations of invasive versus non-invasive
strategy, but subsequent publications failed to disclose HRQOL
data (Mahoney 2002). From the available evidence, it would ap-
pear that improvements in HRQOL as a result of an invasive strat-
egy are modest and last on average no more than 12 months, with
anginal relief likely the key determinant of improved HRQOL.
Findings from studies in the pre-stent era and other reviews
on this topic
We excluded two large trials that were undertaken during the pre-
stent era (TIMI-3b; VANQWISH 1998). The early invasive arm
of TIMI-3b involved cardiac catheterisation an average of 36 hours
after randomisation and coronary revascularisation by coronary
angioplasty or CABG. The early invasive strategy had no effect
on the hard clinical endpoints of death, MI, stroke or the com-
posite of death or MI. As is consistent with more recent clinical
trials, the early invasive strategy reduced recurrent hospitalisation
at both six weeks and one year, with RRs of 0.54 (95% CI 0.40 to
0.74) and 0.79 (95% CI 0.68 to 0.93), respectively (TIMI-3b). In
TIMI-3b, a routine invasive strategy did not reduce the need for
anti-angina medications at one year. In contrast, the VANQWISH
1998 study demonstrated increased risk associated with the early
invasive strategy, which involved cardiac catheterisation an average
of 48 hours after randomisation. In fact, the early invasive strategy
was associated with an increased risk ratio of mortality prior to
hospital discharge, and at one month and one year (RR 3.47 (95%
CI 1.41 to 8.52); RR 2.53, 95% CI 1.19 to 5.42; and RR 1.60,
95% CI 1.08 to 2.37, respectively) (VANQWISH 1998). Simi-
larly, increased risk was associated with the early invasive strategy
for the composite endpoint of death or non-fatal MI. The hazard
of an early invasive strategy on these endpoints ceased to be sig-
nificant by the end of the study (average 23 months). Forty-four
percent of participants in the invasive arm of this trial underwent a
revascularisation procedure, of which 47% involved CABG. The
mortality associated with CABG in the invasive arm was 11.6%,
compared to 3.4% in the conservative arm. Braunwald 2003 has
cited this discrepancy as an explanation for the increased mortality
in the early invasive arm of the VANQWISH 1998 trial. Unsur-
prisingly, rates of background medical therapy were low by con-
temporary standards.
Two older meta-analyses on this topic that included the aforemen-
tioned pre-stent era trials, plus trials that we excluded for reasons
other than low stent use, reached different conclusions than the
ones presented here (Choudhry 2005; Mehta 2005). These re-
views did not include the most recent trials, including the OASIS
5 substudy, LIPSIA-NSTEMI, Italian Elderly ACS and ICTUS
studies. A subsequent meta-analysis included the early trials and
the one-year results from ICTUS (Bavry 2006). The review by
Mehta 2005 associated an invasive strategy with an increased risk
of mortality during the period from randomisation to hospital
discharge (RR 1.61, 95% CI 1.14 to 2.27). When Mehta 2005
analysed the outcomes from hospital discharge to end of follow-
up, the early invasive strategy was associated with reductions in
death and non-fatal MI (RR 0.78, 95% CI 0.64 to 0.94; and RR
0.56, 95% CI 0.47 to 0.68, respectively). When they analysed
trial data from randomisation to the end of follow-up, the invasive
strategy exhibited no effect on mortality, but induced a reduction
in non-fatal MI (RR 0.77, 95% CI 0.67 to 0.89). This Cochrane
review analysed the endpoints at certain time points, since we felt
that combining outcomes collected from studies of short dura-
tion (six months) with those of longer duration (five years) would
not provide a meaningful point estimate (see the ’Characteristics
of included studies’ table). All reviews consistently found a sig-
nificant reduction in recurrent angina and rehospitalisation with
an invasive strategy (Bavry 2006; Choudhry 2005; Mehta 2005).
More recently, a meta-regression analysis that included the earlier
studies but excluded VANQWISH 1998 revealed the benefit of
an invasive strategy - with respect to the endpoint of death or the
composite of death or MI - to be related to the comparator odds
ratio for events in the conservative group (Tarantini 2007). This
implies that the benefit of an invasive strategy relates to the level
of baseline risk in the comparator group. One meta-analysis has
been published since the publication of late follow-up data from
the ICTUS trial. This report, which included the older studies,
identified no benefit of an invasive strategy on the endpoints of
death, MI, or the composite of death or MI (Qayyum 2008). The
findings from our analysis differ, because we excluded older stud-
ies and utilised the reported ’spontaneous’ MI endpoint for our
analysis, in light of the controversy surrounding the routine peri-
procedural biomarker assessment undertaken by the ICTUS trial
authors.
Relevant international guidelines for management of
UA/NSTEMI
Both the current AHA (Anderson 2007; Jneid 2012) and ESC
(Hamm 2011) guidelines make class 1 recommendations for an
invasive strategy in patients who are symptomatic or are consid-
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ered (Level A evidence). The AHA guidelines also endorse the
option of treating stabilised but high-risk (for example troponin-
positive) patients conservatively, however with only Class IIb rec-
ommendation.
Limitations
We have limited the included studies in this Cochrane review
to those from the post-stent era. However, a number of changes
in practice have occurred over this time which limit the applica-
bility of findings from this meta-analysis to contemporary prac-
tice. Of greatest significance, during the post-stent era, is that the
routine use of glycoprotein IIb/IIIa inhibitors gained acceptance
(Boersma 2002). Subsequently, however this practice has been dis-
credited due to the association with increased bleeding (EARLY
ACS 2009). As such, we have presented analyses of studies in
which glycoprotein IIb/IIIa use was routine (Analyses 1 and 2)
as of historical interest, with Analysis 3 being the most relevant
to contemporary practice. Additionally, across this time period
there has been controversy regarding access site efficacy. In partic-
ular, the prospective randomised RIFLE-STEACS study reported
significant benefit for a transradial verse transfemoral approach
for major adverse cardiac and cerebrovascular events (MACCE),
non-CABG-related bleeding and overall net adverse clinical event
(NACE) rate among STEMI patients. Subsequently, the transra-
dial access approach has emerged as the preferred strategy for PCI
and has been adopted as routine practice for invasive strategies
in ACSs. Despite this, a transfemoral strategy was predominant
amongst the included studies in this meta-analysis, which poten-
tially resulted in increased adverse events in the routine invasive
strategy compared with contemporary practice. Additionally, im-
proved outcomes have also resulted from refinement in stent de-
sign with second-generation drug-eluting stents forming the cor-
nerstone of modern PCI practice (Sarno 2012). Both the predom-
inance of a transfemoral approach and use of earlier generation
stents amongst the included studies in this meta-analysis poten-
tially and differentially diminish outcomes in the routine invasive
arm compared with contemporary practice, thus obscuring any
comparison with selective invasive strategies.
These limitations of the current body of evidence form impor-
tant considerations for future trials designed to compare a routine
verse selective invasive strategy in UA/NSTEMI. We recommend
that such studies employ a transradial access route, an antithrom-
botic regime consisting of aspirin and ticagrelor across all study
participants and second generation drug-eluting stents to most
accurately reflect current practice and difference between routine
and selective invasive strategies. Finally, where possible, analyses
should allow for the discrete assessment of outcome measures for
NSTEMIandUAas the heterogeneity of combinedUA/NSTEMI
maymask important intervention risk-benefit differences between
the two entities.
Quality of the evidence
The GRADE approach was employed to interpret findings and
the GRADE profiler (GRADEPRO) allowed us to import data
from Review Manager 5.3 (Review Manager) to create ’Summary
of findings’ tables. The quality of evidence for routine invasive
strategies versus selective invasive strategies (conservative) for un-
stable angina and non-ST elevation myocardial (UA/NSTEMI)
infarction in the stent era (Summary of findings for the main
comparison and Summary of findings 2) ranged from
moderate to low across the different outcomes. This was mainly
due to risk of bias and imprecise results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The most important new finding of this Cochrane review up-
date is the identification of a significantly increased risk of in-
dex death with a routine invasive approach. Conversely, consis-
tent with previous versions of this review (Hoenig 2006; Hoenig
2010), adopting a routine invasive strategy for the management
of UA/NSTEMI patients results in a significant reduction in risk,
from six to 12 months of follow-up, for the two endpoints of re-
fractory angina and rehospitalisation. While the invasive strategy
is associated with an almost two-fold increase in the risk of peri-
procedural myocardial infarction (MI), the data also suggest a sig-
nificant risk reduction in the rate of MI assessed at three to five
years. The importance of peri-procedural infarction continues to
be a subject of dispute, with recent suggestions that this endpoint
lacks prognostic significance.Hence, the early risks associated with
a routine invasive strategy must be weighed against potential long-
term benefits in clinical endpoints. However, longer term follow-
up of more contemporary trials may find this benefit to be attenu-
ated with more optimal use of medical therapies, the deployment
of more rigorous risk stratification protocols in the days immedi-
ately following onset of the acute event, and a more conservative/
selective invasive approach with high invasive percentages. The
benefits of a routine invasive strategy may be more meaningful in
higher-risk patients, among whom the number needed to treat for
an additional beneficial outcome (NNTB) should be less.
The increased risk of index death noted with the inclusion of the
Italian Elderly ACS and the LIPSIA-NSTEMI trials in this review
update must be interpreted in the context of the disproportionate
representation of populations with known adverse predictors. In-
creased mortality risk has been associated with both elderly pop-
ulations (Italian Elderly ACS) and routine glycoprotein IIb/IIIa
inhibitor use (LIPSIA-NSTEMI), both of which contribute to ex-
cess event rates among people treated using a routinely invasive
strategy. A more considered approach in the elderly population
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and a selective use of glycoprotein IIb/IIIa inhibitors is now rec-
ommended in most international guidelines (Hamm 2011; Jneid
2012). The finding that inclusion of two such populations resulted
in an overall increase in index mortality rate associated with an
invasive strategy strengthens the current recommendations. Due
to the attendant bleeding risk and subsequent increased morbid-
ity/mortality, glycoprotein IIb/IIIa inhibitors should only be used
selectively in people undergoing invasive treatment. Similarly, in
elderly populations, a selective invasive approach is appropriate,
as invasive interventions carry increased risk, with decisions based
upon markers of risk - in particular, troponin status.
In the all-study analysis, evidence incorporating intermediate end-
points with all included studies (or most of the studies) failed
to show appreciable benefit with invasive strategies for unstable
angina and non-ST elevationMI compared to conservative strate-
gies in all-cause mortality and death or non-fatal MI at six to 12
months. Evidence showed risk reduction in MI, refractory angina
and rehospitalisation with routine invasive strategies compared to
conservative (selective invasive) strategies at six to 12 months fol-
low-up. However, routine invasive strategies were seen to be asso-
ciated with a relatively high risk (almost double the risk) of pro-
cedure-related MI, and increased risk of bleeding complications.
This systematic analysis of published RCTs supports the conclu-
sion that, in people with unstable angina and non-ST elevation
MI (UA/NSTEMI), a selectively invasive (conservative) strategy
based on clinical risk for recurrent events is the preferred manage-
ment strategy.
Implications for research
This Cochrane review highlights the need for further research on
treatment strategies for UA/NSTEMI. To date, published trials
have enrolled heterogeneous populations of patients with variable
levels of risk and event rates, subjected to a variety of co-inter-
ventions, and used outcome measures subject to variable defini-
tion and timing. Risk stratification of the participants in each trial
based upon a validated risk system (e.g. the TIMI risk score) would
allow for more meaningful meta-analyses of available data, and
provide a risk score or an absolute event rate above which an inva-
sive strategy is expected to significantly improve outcomes. Clearly
as medical therapies for UA/NSTEMI improve, progressively less
absolute benefit is likely to be gained via aggressive interventions.
Hence, the level of baseline risk at which an invasive intervention
becomes warranted is likely to be a moving target. Another major
limitation to the analyses undertaken in this review is the under-
powering of trials in terms of assessing the effects of an invasive
strategy on all-cause mortality, due to the short length of follow-
up. Inadequate numbers also hinder the interpretation of sub-
group analyses. This could be addressed in future clinical trials by
ensuring that sufficient events accrue by way of larger sample sizes,
the enrolment of higher-risk participants, and longer durations of
follow-up. Finally, further research is required to better define the
benefits and hazards of an invasive strategy in females.
Given the support for a routine invasive strategy in the manage-
ment of non-ST-elevation ACS, it has become difficult to jus-
tify the inclusion of a selectively invasive (conservative) arm when
designing RCTs, and this is reflected in the paucity of recent
research comparing a selective versus routine invasive approach.
However, our findings suggest that including a selectively invasive
arm is required. Using a routine invasive strategy amongst the el-
derly requires particular investigation. In light of the results of the
ACUITY and EARLY ACS 2009 studies, studies responsible for
discrediting the routine use of glycoprotein IIb/IIIa inhibitors as
part of an invasive strategy, it is also prudent to re-evaluate conser-
vative and invasivemanagement strategies in light of the significant
potential confounding effect observed in a number of influential
studies. Indeed, these studies warrant repeating, albeit employing
a highly-selective glycoprotein IIb/IIIa inhibitor strategy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
FRISC-II
Methods Prospective, randomised, multicentre trial with parallel groups. Invasve and non-invasive
treatments compared by factorial design
Participants 2457 participants with anginal pain within the last 48 hours and ST depression or
elevated cardiac markers.
Overall impression of participant risk level: intermediate-high
Interventions Conservative arm: aspirin, beta blocker, statin, ACEI, dalteparin or UFH.
Invasive arm: as above and routine angiography (average time to angiography: 4 days).
10% glycoprotein 2b/3a receptor antagonist use
Each strategy further randomised to placebo or dalteparin in a double-blind fashion
Outcomes Death all causes (6, 12, 24 months, 5 years), MI (6, 12, 24 months, 5 years), refractory
angina (6 months), death or non-fatal MI (6, 12, 24 months, 5 years), rehospitalisation
(6 weeks, 6, 12 months), procedural MI, bleeding, contrast allergy
Notes Sponsored by Pharmacia and Upjohn (a subsidiary of Pfizer).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation algorithm
was not disclosed. An independent organ-
isation performed randomisation. There
were no significant differences in baseline
characteristics of the groups, which sup-
ports minimal selection bias
Allocation concealment (selection bias) Low risk An independent organisation performed
randomisation by telefax (Clinical Data
Care, Lund, Sweden)
Blinding (performance bias and detection
bias)
All outcomes
High risk Allocation to invasive and non-invasive
strategies was open (allocation to long-term
dalteparin treatmentwith placebowas dou-
ble-blinded)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open.
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FRISC-II (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was equivalent between groups.
The trial randomised 1222 participants to
invasive, with 32 lost to 6-month follow-
up (2.62%) compared with 1235 partici-
pants randomised to conservative manage-
ment and 49 lost to 6-month follow-up
(3.96%). The trial used intention-to-treat
(ITT) analysis
Other bias Low risk The sponsoring pharmaceutical company
employed continuous source-data verifica-
tion of all case-record forms by external
monitors. An independent clinical-event
committee and a data and safety monitor-
ing board adjudicated adverse events
ICTUS
Methods Prospective, randomised, multicentre trial.
Participants 1200 participants with accelerating angina or angina at rest in the preceding 24 hours
and an elevated cardiac troponin T > 0.3 µg/L and either ischaemic ECG changes or a
documented history of coronary artery disease (CAD) (previous catheterization, history
of myocardial infarction (MI) or positive exercise test).
Overall impression on level of risk in participants: high risk; all participants had a positive
troponin test on randomisation
Interventions Conservative arm: aspirin, enoxaparin, statin, clopidogrel.
Invasive arm: as above, abciximab and routine angiography (median time to angiography:
23 hours) postrandomisation. 94% glycoprotein 2b/3a receptor antagonist use
Outcomes Death all causes (1, 3 and 4 years), MI (1 and 3 years), rehospitalisation (1 and 3 years)
, major bleeding during the index admission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted-block randomisation, with strat-
ification according to site, with block size
randomly chosen to be 4, 6 or 8. Baseline
characteristics were comparable between
groups
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ICTUS (Continued)
Allocation concealment (selection bias) Low risk Eligibility was confirmed prior to contact-
ing a central telephone system for alloca-
tion
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Members of an independent clinical end-
points committee, who were blinded to
treatment allocation of participants, adju-
dicated endpoints
Incomplete outcome data (attrition bias)
All outcomes
Low risk Six participants were lost to follow-up. The
trial used ITT analysis
Other bias Unclear risk Clopidogrel was more common at dis-
charge for early invasive (61%) versus se-
lective invasive (49%) strategies. There was
sponsorship from Eli Lilly, Sanofi-Synthe-
labo, Aventis, Pfizer and Medtronic. Spon-
sors were reported to have had no involve-
ment in the design of the study, data col-
lection or analysis, or the writing of the
manuscript
Italian Elderly ACS
Methods Prospective, randomised, multicentre trial
Participants 313 participants with symptoms suggestive of acute myocardial ischaemia at rest within
48 hours before randomisation and ischaemic ECG changes (transient or persistent ST-
segment elevation or depression > 0.5 mm but < 1 mm in the case of ST-elevation or
persistent and definite T wave inversion > 1 mm in at least 2 contiguous leads) and/or
elevate levels (> upper limit of normal) of creatine kinase-myocardial band (CK-MB) or
cTn
Overall impression of level of risk in participants: high risk; all participants were elderly
(≥ 75 years of age)
Interventions Early aggressive strategy (coronary angiography and, when indicated, revascularization
within 72 hours) or initially conservative strategy (angiography and revascularization
only for recurrent ischaemia)
Outcomes All-cause death (6 months, 1 year), MI (6 months, 1 year), rehospitalisation (6 month,
1 year), major bleeding (6 months, 1 year), days spent in hospital (6 months, 1 year),
stroke (6 month, 1 year)
Notes
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Italian Elderly ACS (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list, stratified by the
centre, and randomly balanced every 4, 6
or 8 participants for each centre
Allocation concealment (selection bias) Low risk Centralised randomisation was immedi-
ately made available to the investigator
upon registering the participant on the
website http://elderly.altavianet.it
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments were collected in a web-based
case report form. This was audited/super-
vised by study monitors who visit study
centres. An independent event adjudica-
tion committee adjudicated all serious ad-
verse events on the basis of the review of
the original source documents
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four participants were lost to follow-up
and 2 participants withdrew. Attrition was
equal between groups. All recruited partici-
pants were accounted for in analysis of each
group on an ITT basis
Other bias Low risk There was no industry sponsorship.
LIPSIA-NSTEMI
Methods Prospective, randomised, multicentre trial comparing immediate versus early versus se-
lective invasive strategies
Participants 602 participants with NSTEMI (ischaemic symptoms that were increasing or occurred
at rest, with the last episode < 24 hours before randomisation plus elevated troponin
T level ≥ 0.1 ng/mL) were admitted across 6 tertiary care centres with 24 hour PCI
facilities
Overall impression of level of risk in participants: high risk; all participants with elevated
troponin (T level ≥ 0.1 ng/mL)
Interventions Immediate invasive strategy: < 2 hours after randomisation; early invasive strategy: 10
to 48 hours after randomisation; selective invasive only if refractory ischaemia
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LIPSIA-NSTEMI (Continued)
Outcomes Primary endpoint: peak creatine kinase (CK)-myocardial band (MB) activity during in-
dex admission. Secondary clinical endpoints were the composite of death and non-fatal
infarction; death, non-fatal infarction and refractory ischaemia; death, non-fatal infarc-
tion, refractory ischaemia and rehospitalisation for unstable angina within 6 months
Notes Though results were expressed in terms of the 3 groups of randomisation (immediate
versus early versus selective invasive) for the purposes of this review, the immediate and
early invasive strategies were grouped and considered “early invasive”, whereas the criteria
for the selective invasive was most consistent with a conservative strategy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation system utilising permuted
block randomisation performed with strat-
ification according to site
Allocation concealment (selection bias) Low risk Centralised web-based allocation conceal-
ment.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants were lost to follow-up,
1 each from the immediate invasive and
the selective invasive groups. The trial used
ITT analysis
Other bias Unclear risk The study was supported by free tirofiban
medication
from MSD SHARP & DOHME GmbH,
and Iroko Pharmaceutical
OASIS 5
Methods Randomised, multicentre, prospectively designed substudy of the OASIS 5 trial (a dou-
ble-blinded trial in which fondaparinux was compared with enoxaparin in participants
with UA/NSTEMI)
Participants 184 female participants were recruited when the OASIS 5 main trial was stopped. These
participants presented to hospital with symptoms of UA or MI without persistent ST
elevation and at least 2 of: age ≥ 60 years, troponin T or I or CK-MB above the upper
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OASIS 5 (Continued)
limit of normal or ECG changes compatible with ischaemia (ST depression ≥ 1 mm in
2 contiguous leads or T wave inversion > 3 mm or any dynamic ST shift or transient ST
elevation)
Overall impression of level of risk in participants: intermediate risk
Interventions Conservative/selective invasive arm: with coronary angiography only if symptoms or
signs of severe ischaemia
Invasive arm: routine coronary angiography within 4 days of admission and, if appro-
priate, revascularisation within 7 days of admission
Outcomes Primary endpoint was the composite of death, MI or stroke at 2 years. Secondary out-
comes included the following
1. Death, MI, and stroke evaluated separately.
2. Composites of death, MI and death, MI, stroke or refractory ischaemia.
Notes Recruitment ceased early and sample sizes curtailed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated permuted block ran-
domisation, stratified according to study
centre using predetermined site specific
randomisation ratios of 1:1, 1:2 or 2:1 for
early intervention:delayed intervention in
block sizes of 2 and 4. There were no signif-
icant differences in baseline characteristics
of groups
Allocation concealment (selection bias) Low risk Allocations were concealed at the Cana-
dian Cardiovascular Collaboration Project
Office, Population Health Research Insti-
tute, McMaster University and Hamilton
Health Sciences, Hamilton, Canada and
accessed via 24-hour computerized tele-
phone service
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A central committee of clinicians blinded
to the allocated management strategy ad-
judicated death classified by cause, MI, re-
fractory ischaemia, stroke andmajor bleed-
ing
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OASIS 5 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine participants were lost to long-term
follow-up, equally distributed between
routine invasive (5) and selective invasive
(4) strategies. The trial used ITT analysis
Other bias Unclear risk Curtailment in sample size as well as fol-
low-up time. Sponsored by Sanofi-Aventis,
Organon andGlaxoSmithKline. The spon-
sor reportedly did not have a role in the
study design; the collection, analysis, or in-
terpretation of the data; the preparation,
review or approval of the manuscript
RITA-3
Methods Prospective, randomised mulitcentre trial with parallel groups
Participants 1810 participants with chest pain within the last 72 hours, a documented history of
CAD, and one of the following: ischaemic ECG changes or Q waves suggesting previous
MI or proven CAD on angiogram. The trial excluded those with probable evolving MI
or those with elevated cardiac biomarkerss (2x) before randomisation.
Overall impression on level of risk in participants: intermediate
Interventions Conservative arm: aspirin, beta blocker, enoxaparin
Invasive arm: as above and routine angiography (median time to angiography: 2 days).
25% glycoprotein 2b/3a receptor antagonist use
Outcomes Death all causes (4, 12, 24 months, 5 years), MI (4, 12, 24 months, 5 years), refractory
angina (4,12mo), death or non-fatal MI (4, 12, 24months, 5 years), procedural bleeding
and MI
Notes Recruitment from November 1997 to October 2001.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The methodology of randomisation was
not disclosed. The baseline characteristics
between groups were comparable
Allocation concealment (selection bias) Low risk Central telephone service.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
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RITA-3 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for at 2
years, 99.8% at 3 years and 59% at 5 years
follow-up. The trial used ITT analysis
Other bias Low risk We did not detect any other sources of bias.
TACTICS-TIMI 18
Methods Prospective, randomised, multicentre trial with parallel groups
Participants 2220 participants with angina (accelerating or prolonged) at rest in preceding 24 hours
and at least 1 of the following: ischaemic ECG changes, elevated cardiac markers or
documented CAD (previous catheterisation, revascularisation or MI)
Overall impression on level of risk in participants: variable; subanalyses reported on
TIMI risk score and troponin status
Interventions Conservative arm: aspirin, beta blocker, UFH, tirofiban, statin
Invasive arm: as above and routine angiography (median time to angiography: 22 hours)
. 94% glycoprotein 2b/3a receptor antagonist use
Outcomes Death all causes (30 days, 6 months), refractory angina (6 months), death or MI (30
days, 6 months), rehospitalisation (30 days, 6 months)
Notes Recruitment between December 1997 and December 1999.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methodology of randomisation was not
disclosed. Baseline characteristics between
groups were comparable
Allocation concealment (selection bias) Low risk Centralised system.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A blinded committee adjudicated end-
points.
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TACTICS-TIMI 18 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for by the
end of the trial; the trial used ITT analysis
Other bias Unclear risk Sponsored by Merck.
VINO
Methods Prospective, randomised, multicentre trial with parallel groups
Participants 131 participants with ischaemic chest pain lasting more than 20 mins (within the pre-
ceding 24 hours) and ECG changes and elevated cardiac markers
Overall impression on level of risk in participants: high; all participants were cardiac
biomarker positive
Interventions Conservative arm: aspirin, beta blocker, UFH
Invasive arm: as above and routine angiography (average time to angiography: 6.2 hours)
. 0% glycoprotein 2b/3a receptor antagonist use
Outcomes Death all causes (30 days, 6 months), MI (30 days, 6 months), death or non-fatal MI
(30 days, 6 months), rehospitalisation (30 days, 6 months)
Notes Recruitment commenced May 1998.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequentially numbered envelopes.
Allocation concealment (selection bias) Low risk Sealed envelope.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for by the
end of the trial; the trial used ITT analysis
Other bias Low risk We did not detect any other sources of bias.
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ACEI = angiotensin converting enzyme inhibitors; UFH = unfractionated heparin; MI = myocardial infarction; ITT = intention to
treat; ECG = electrocardiogram; UA = unstable angina; STEMI = ST segment elevation myocardial infarction; CAD = coronary
artery disease
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ABOARD This trial randomised 352 participants with acute coronary syndrome (ACS) without ST-segment elevation
and a TIMIscore of > 3 to an immediate or delayed invasive strategy
ACUITY This trial randomised 13819 participants with acute coronary syndromes (ACS) undergoing an invasive strategy
to 1 of 3 antithrombotic regimes: unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor,
bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone
EARLYACS This trial randomly assigned 9492 participants with UA/NSTEMI, all of whom were assigned to an invasive
strategy, to receive either early routine administration of eptifibatide or to delayed provisional administration
Eisenberg 2005 This trial included participants with STEMI and, while index and late death are reported, outcomes for UA/
NSTEMI are not reported separately. Also, this was a trial of 88 participants where the primary endpoints
related to quality of life
ELISA This trial randomised 220 participants with ACS to early angiography without tirofiban pretreatment (early
strategy) or to delayed angiography after 24 to 48 hours of pre-treatment with tirofiban (late strategy)
GUSTO2b 2003 This was a post-hoc analysis from a trial designed to compare hirudin to heparin in UA/NSTEMI participants
Hsin 2010 Participants were randomised to early invasive and early conservative treatment arms. The early-conservative
treatment arm was managed medically for the first 48 hours before undergoing routine coronary angiogram
at 48 hours after enrolment, consistent with a “delayed invasive” rather than true conservative management.
Thus this study does not meet the review;s criteria for conservative management strategy
ISAR-COOL This trial included UA/NSTEMI participants that were all due to have angiography. This trial compared 2
invasive strategies depending on whether angiography was undertaken at < 6 hours or at 3 to 5 days. Hence,
this trial compared 2 different invasive strategies i.e. early or delayed invasive and is inappropriate for this
review
MATE 1998 This trial was undertaken in the pre-stent era and included participants with STEMI
MITI 2000 This was not a randomised controlled trial (RCT). The data are extracted from a registry
OPTIMA This trial randomised 251 participants with non-ST-elevation ACS who were eligible for PCI to either imme-
diate or deferred (24 to 48 hours) PCI
Teixeira 2009 This was not a RCT but an observational comparative study.
TIMACS This study randomised 3031 participants with all forms of ACS (not specifically UA/NSTEMI patients), to
undergo early (< 36 hours) or delayed (> 36 hours) intervention
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(Continued)
TIMI-3b This trial was undertaken in the pre-stent era.
TRUCS 2000 This trial was deemed inappropriate to this review since the included participants were admitted with recurrent
angina 48 hours after the index case of unstable angina. Hence, the participants in this trial had all been
managed conservatively for at least 48 hours after their index chest pain, and had to suffer another bout of
angina before randomisation was considered. The included studies in this review require that participants were
randomised at index presentation. This study, by definition, only considered participants with Braunwald class
IIIb or IIIc unstable angina, and is therefore dissimilar enough from the included studies to warrant exclusion
VANQWISH 1998 This trial was undertaken in the pre-stent era and included participants treated with thrombolysis
Yu 2011 All participants underwent coronary angiogram prior to randomisation into PCI and conservative therapy.
Thus, this study does not meet the review’s criteria for conservative management
Zhang 2010 Eight hundred and fifteen non-ST-elevation ACS patients undergoing an invasive strategy were randomly
assigned to undergo early (< 24hrs) or delayed (> 24hrs) intervention
Zhao 2005 This study doesn’t meet this review’s stent requirement.
UA = unstable angina; NSTEMI = non ST segment myocardial infarction; STEMI = ST segment elevation myocardial infarction; ACS
= acute coronary syndrome; PCI = percutaneous coronary intervention
Characteristics of ongoing studies [ordered by study ID]
Dimitrov 2013
Trial name or title Timing of invasive strategy in acute coronary syndrome without ST segment elevation in groups of patients
with different ischemic risk
Methods Randomized controlled trial
Participants 178 participants with UA/NSTEMI
Interventions Early invasive (coronary angiography-SCAG and percutaneous intervention-PCI in the first 24 hours after
admission); selective invasive (attempt for medical stabilization and proceeding to SCAG only in case of
angina recurrence and/or evidence of inducible myocardial ischaemia
Outcomes Choice of an early invasive strategy in participants with acute coronary syndrome without ST elevation in
the presence of high risk features is associated with a reduced incidence of MACE compared to a selective
invasive strategy. In the subgroups of participants without high risk characteristics the advantages of early
versus selective are not as clear
Starting date
Contact information University Hospital St. Ekaterina, Sofia, Bulgaria
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Dimitrov 2013 (Continued)
Notes Full study not yet analysed/published. We extracted details from a conference abstract
UA = unstable angina; NSTEMI = non ST segment myocardial infarction; SCAG= Selective coronary angiography; PCI = Percutaneous
coronary intervention; MACE = Major adverse cardiac events
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D A T A A N D A N A L Y S E S
Comparison 1. All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Index death 6 8094 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.02, 2.34]
1.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
2 3383 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.84, 3.31]
1.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
4 4711 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.88, 2.48]
2 Early death 4 4345 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.70, 2.00]
2.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.76, 2.51]
2.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 2125 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.31, 3.33]
3 Intermediate death 8 8915 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.18]
3.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
3 4020 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.27]
3.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
5 4895 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.48, 1.49]
4 Late death 3 5467 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.76, 1.08]
4.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 1200 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.74, 1.67]
4.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 4267 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.04]
5 Index myocardial infarction 7 8694 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.65, 1.80]
5.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
3 3983 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.51, 1.83]
5.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
4 4711 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.59, 2.55]
6 Early myocardial infarction 4 4345 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.43, 1.08]
6.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.35, 0.79]
6.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 2125 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.52, 1.44]
7 Intermediate myocardial
infarction
8 8915 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.63, 1.00]
7.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
3 4020 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.56, 1.60]
7.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
5 4895 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.60, 0.89]
8 Late myocardial infarction 3 5467 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.67, 0.92]
8.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 1200 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.66, 1.55]
8.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 4267 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.63, 0.90]
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9 Index death or non-fatal
myocardial infarction
4 6618 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.59, 2.21]
9.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.51, 1.17]
9.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.75, 2.86]
10 Early death or non-fatal
myocardial infarction
2 2351 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.45, 0.92]
10.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.48, 0.94]
10.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
1 131 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.06, 1.39]
11 Intermediate death or non-fatal
myocardial infarction
7 7715 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.71, 1.20]
11.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
2 2820 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.59, 1.60]
11.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
5 4895 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.62, 1.32]
12 Intermediate death or non-fatal
myocardial infarction; gender
subanalysis
5 6975 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.67, 0.91]
12.1 Male 4 4454 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.62, 0.87]
12.2 Female 5 2521 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.65, 1.16]
13 Late death or non-fatal
myocardial infarction
3 5467 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.73, 1.08]
13.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 1200 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.87, 1.63]
13.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 4267 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.72, 0.92]
14 Intermediate refractory angina 5 8287 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.79]
14.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
3 4020 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.42, 1.08]
14.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 4267 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.50, 0.64]
15 Intermediate rehospitalisation 6 6921 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.63, 0.94]
15.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
3 4020 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.61, 1.14]
15.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 2901 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.54, 0.94]
Comparison 2. Safety endpoints
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Procedure-related myocardial
infarction
5 6380 Risk Ratio (M-H, Random, 95% CI) 1.87 [1.47, 2.37]
2 Bleeding 6 7584 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.30, 2.31]
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Analysis 1.1. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 1 Index death.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 1 Index death
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 6/586 5/577 12.3 % 1.18 [ 0.36, 3.85 ]
TACTICS-TIMI 18 16/1114 8/1106 24.1 % 1.99 [ 0.85, 4.62 ]
Subtotal (95% CI) 1700 1683 36.4 % 1.67 [ 0.84, 3.31 ]
Total events: 22 (Invasive), 13 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 13/1222 11/1235 26.9 % 1.19 [ 0.54, 2.66 ]
Italian Elderly ACS 8/154 5/159 14.3 % 1.65 [ 0.55, 4.94 ]
RITA-3 14/895 6/915 19.0 % 2.39 [ 0.92, 6.18 ]
VINO 1/64 3/67 3.4 % 0.35 [ 0.04, 3.27 ]
Subtotal (95% CI) 2335 2376 63.6 % 1.48 [ 0.88, 2.48 ]
Total events: 36 (Invasive), 25 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.88, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 4035 4059 100.0 % 1.54 [ 1.02, 2.34 ]
Total events: 58 (Invasive), 38 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.2. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 2 Early death.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 2 Early death
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
TACTICS-TIMI 18 25/1114 18/1106 42.2 % 1.38 [ 0.76, 2.51 ]
Subtotal (95% CI) 1114 1106 42.2 % 1.38 [ 0.76, 2.51 ]
Total events: 25 (Invasive), 18 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
OASIS 5 4/92 1/92 5.5 % 4.00 [ 0.46, 35.11 ]
RITA-3 26/895 24/915 46.5 % 1.11 [ 0.64, 1.91 ]
VINO 1/64 5/67 5.8 % 0.21 [ 0.03, 1.74 ]
Subtotal (95% CI) 1051 1074 57.8 % 1.01 [ 0.31, 3.33 ]
Total events: 31 (Invasive), 30 (Conservative)
Heterogeneity: Tau2 = 0.56; Chi2 = 3.71, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 2165 2180 100.0 % 1.18 [ 0.70, 2.00 ]
Total events: 56 (Invasive), 48 (Conservative)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.08, df = 3 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 1.3. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 3 Intermediate death.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 3 Intermediate death
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 15/604 15/596 11.6 % 0.99 [ 0.49, 2.00 ]
LIPSIA-NSTEMI 21/400 13/200 12.4 % 0.81 [ 0.41, 1.58 ]
TACTICS-TIMI 18 37/1114 39/1106 18.7 % 0.94 [ 0.61, 1.47 ]
Subtotal (95% CI) 2118 1902 42.7 % 0.92 [ 0.66, 1.27 ]
Total events: 73 (Invasive), 67 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 27/1222 48/1235 18.0 % 0.57 [ 0.36, 0.90 ]
Italian Elderly ACS 19/154 22/159 14.8 % 0.89 [ 0.50, 1.58 ]
OASIS 5 8/92 1/92 2.0 % 8.00 [ 1.02, 62.68 ]
RITA-3 41/895 36/915 18.8 % 1.16 [ 0.75, 1.80 ]
VINO 2/64 9/67 3.7 % 0.23 [ 0.05, 1.04 ]
Subtotal (95% CI) 2427 2468 57.3 % 0.85 [ 0.48, 1.49 ]
Total events: 97 (Invasive), 116 (Conservative)
Heterogeneity: Tau2 = 0.23; Chi2 = 12.34, df = 4 (P = 0.02); I2 =68%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 4545 4370 100.0 % 0.87 [ 0.64, 1.18 ]
Total events: 170 (Invasive), 183 (Conservative)
Heterogeneity: Tau2 = 0.08; Chi2 = 12.68, df = 7 (P = 0.08); I2 =45%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.4. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 4 Late death.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 4 Late death
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 45/604 40/596 16.4 % 1.11 [ 0.74, 1.67 ]
Subtotal (95% CI) 604 596 16.4 % 1.11 [ 0.74, 1.67 ]
Total events: 45 (Invasive), 40 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 117/1222 124/1235 42.0 % 0.95 [ 0.75, 1.21 ]
RITA-3 102/895 132/915 41.6 % 0.79 [ 0.62, 1.01 ]
Subtotal (95% CI) 2117 2150 83.6 % 0.87 [ 0.72, 1.04 ]
Total events: 219 (Invasive), 256 (Conservative)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 2721 2746 100.0 % 0.90 [ 0.76, 1.08 ]
Total events: 264 (Invasive), 296 (Conservative)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.35, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.28), I2 =13%
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Analysis 1.5. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 5 Index myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 5 Index myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 9/586 9/577 13.4 % 0.98 [ 0.39, 2.46 ]
LIPSIA-NSTEMI 44/400 14/200 18.3 % 1.57 [ 0.88, 2.80 ]
TACTICS-TIMI 18 27/1114 44/1106 19.9 % 0.61 [ 0.38, 0.98 ]
Subtotal (95% CI) 2100 1883 51.7 % 0.96 [ 0.51, 1.83 ]
Total events: 80 (Invasive), 67 (Conservative)
Heterogeneity: Tau2 = 0.21; Chi2 = 6.25, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.12 (P = 0.91)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 68/1222 31/1235 20.7 % 2.22 [ 1.46, 3.36 ]
Italian Elderly ACS 3/154 5/159 8.4 % 0.62 [ 0.15, 2.55 ]
RITA-3 17/895 15/915 16.7 % 1.16 [ 0.58, 2.31 ]
VINO 0/64 3/67 2.6 % 0.15 [ 0.01, 2.84 ]
Subtotal (95% CI) 2335 2376 48.3 % 1.22 [ 0.59, 2.55 ]
Total events: 88 (Invasive), 54 (Conservative)
Heterogeneity: Tau2 = 0.28; Chi2 = 7.34, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 4435 4259 100.0 % 1.08 [ 0.65, 1.80 ]
Total events: 168 (Invasive), 121 (Conservative)
Heterogeneity: Tau2 = 0.28; Chi2 = 19.99, df = 6 (P = 0.003); I2 =70%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.63), I2 =0.0%
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Analysis 1.6. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 6 Early myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 6 Early myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
TACTICS-TIMI 18 34/1114 64/1106 46.3 % 0.53 [ 0.35, 0.79 ]
Subtotal (95% CI) 1114 1106 46.3 % 0.53 [ 0.35, 0.79 ]
Total events: 34 (Invasive), 64 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 3.08 (P = 0.0021)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
OASIS 5 4/92 3/92 8.7 % 1.33 [ 0.31, 5.79 ]
RITA-3 30/895 34/915 40.5 % 0.90 [ 0.56, 1.46 ]
VINO 1/64 5/67 4.5 % 0.21 [ 0.03, 1.74 ]
Subtotal (95% CI) 1051 1074 53.7 % 0.87 [ 0.52, 1.44 ]
Total events: 35 (Invasive), 42 (Conservative)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 2165 2180 100.0 % 0.68 [ 0.43, 1.08 ]
Total events: 69 (Invasive), 106 (Conservative)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.79, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 2.26, df = 1 (P = 0.13), I2 =56%
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Analysis 1.7. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 7 Intermediate myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 7 Intermediate myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 22/604 27/596 11.6 % 0.80 [ 0.46, 1.40 ]
LIPSIA-NSTEMI 53/400 16/200 12.2 % 1.66 [ 0.97, 2.82 ]
TACTICS-TIMI 18 53/1114 76/1106 20.0 % 0.69 [ 0.49, 0.97 ]
Subtotal (95% CI) 2118 1902 43.7 % 0.95 [ 0.56, 1.60 ]
Total events: 128 (Invasive), 119 (Conservative)
Heterogeneity: Tau2 = 0.15; Chi2 = 7.42, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.19 (P = 0.85)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 105/1222 143/1235 25.7 % 0.74 [ 0.58, 0.94 ]
Italian Elderly ACS 11/154 17/159 7.8 % 0.67 [ 0.32, 1.38 ]
OASIS 5 7/92 9/92 5.0 % 0.78 [ 0.30, 2.00 ]
RITA-3 34/895 44/915 15.5 % 0.79 [ 0.51, 1.22 ]
VINO 2/64 10/67 2.2 % 0.21 [ 0.05, 0.92 ]
Subtotal (95% CI) 2427 2468 56.3 % 0.73 [ 0.60, 0.89 ]
Total events: 159 (Invasive), 223 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.97, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.14 (P = 0.0017)
Total (95% CI) 4545 4370 100.0 % 0.79 [ 0.63, 1.00 ]
Total events: 287 (Invasive), 342 (Conservative)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.54, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 0.85, df = 1 (P = 0.36), I2 =0.0%
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Analysis 1.8. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 8 Late myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 8 Late myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 40/604 39/596 14.8 % 1.01 [ 0.66, 1.55 ]
Subtotal (95% CI) 604 596 14.8 % 1.01 [ 0.66, 1.55 ]
Total events: 40 (Invasive), 39 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 141/1222 195/1235 66.2 % 0.73 [ 0.60, 0.89 ]
RITA-3 46/895 57/915 18.9 % 0.83 [ 0.57, 1.20 ]
Subtotal (95% CI) 2117 2150 85.2 % 0.75 [ 0.63, 0.90 ]
Total events: 187 (Invasive), 252 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
Total (95% CI) 2721 2746 100.0 % 0.78 [ 0.67, 0.92 ]
Total events: 227 (Invasive), 291 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Chi2 = 1.61, df = 1 (P = 0.21), I2 =38%
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Analysis 1.9. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 9 Index death or non-fatal myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 9 Index death or non-fatal myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
TACTICS-TIMI 18 38/1114 49/1106 31.4 % 0.77 [ 0.51, 1.17 ]
Subtotal (95% CI) 1114 1106 31.4 % 0.77 [ 0.51, 1.17 ]
Total events: 38 (Invasive), 49 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 78/1222 38/1235 32.1 % 2.07 [ 1.42, 3.03 ]
RITA-3 31/895 21/915 28.8 % 1.51 [ 0.87, 2.61 ]
VINO 1/64 6/67 7.8 % 0.17 [ 0.02, 1.41 ]
Subtotal (95% CI) 2181 2217 68.6 % 1.46 [ 0.75, 2.86 ]
Total events: 110 (Invasive), 65 (Conservative)
Heterogeneity: Tau2 = 0.20; Chi2 = 5.77, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 3295 3323 100.0 % 1.14 [ 0.59, 2.21 ]
Total events: 148 (Invasive), 114 (Conservative)
Heterogeneity: Tau2 = 0.31; Chi2 = 15.76, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 2.52, df = 1 (P = 0.11), I2 =60%
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Analysis 1.10. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 10 Early death or non-fatal myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 10 Early death or non-fatal myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
TACTICS-TIMI 18 52/1114 77/1106 94.6 % 0.67 [ 0.48, 0.94 ]
Subtotal (95% CI) 1114 1106 94.6 % 0.67 [ 0.48, 0.94 ]
Total events: 52 (Invasive), 77 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
VINO 2/64 7/67 5.4 % 0.30 [ 0.06, 1.39 ]
Subtotal (95% CI) 64 67 5.4 % 0.30 [ 0.06, 1.39 ]
Total events: 2 (Invasive), 7 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1178 1173 100.0 % 0.64 [ 0.45, 0.92 ]
Total events: 54 (Invasive), 84 (Conservative)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 2.42 (P = 0.015)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
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Analysis 1.11. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 11 Intermediate death or non-fatal myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 11 Intermediate death or non-fatal myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
LIPSIA-NSTEMI 74/400 29/200 16.0 % 1.28 [ 0.86, 1.89 ]
TACTICS-TIMI 18 81/1114 105/1106 19.5 % 0.77 [ 0.58, 1.01 ]
Subtotal (95% CI) 1514 1306 35.5 % 0.97 [ 0.59, 1.60 ]
Total events: 155 (Invasive), 134 (Conservative)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.30, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.12 (P = 0.90)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 127/1222 174/1235 21.4 % 0.74 [ 0.60, 0.91 ]
Italian Elderly ACS 28/154 17/159 11.7 % 1.70 [ 0.97, 2.98 ]
OASIS 5 13/92 10/92 7.9 % 1.30 [ 0.60, 2.81 ]
RITA-3 68/895 76/915 18.4 % 0.91 [ 0.67, 1.25 ]
VINO 4/64 15/67 5.0 % 0.28 [ 0.10, 0.80 ]
Subtotal (95% CI) 2427 2468 64.5 % 0.91 [ 0.62, 1.32 ]
Total events: 240 (Invasive), 292 (Conservative)
Heterogeneity: Tau2 = 0.11; Chi2 = 13.25, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 0.50 (P = 0.61)
Total (95% CI) 3941 3774 100.0 % 0.93 [ 0.71, 1.20 ]
Total events: 395 (Invasive), 426 (Conservative)
Heterogeneity: Tau2 = 0.07; Chi2 = 17.84, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Invasive Conservative
68Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the
stent era (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 12 Intermediate death or non-fatal myocardial infarction; gender subanalysis.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 12 Intermediate death or non-fatal myocardial infarction; gender subanalysis
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Male
FRISC-II 84/872 132/834 16.7 % 0.61 [ 0.47, 0.79 ]
Italian Elderly ACS 50/76 65/81 20.9 % 0.82 [ 0.67, 1.00 ]
RITA-3 38/545 59/583 10.3 % 0.69 [ 0.47, 1.02 ]
TACTICS-TIMI 18 55/719 70/744 12.4 % 0.81 [ 0.58, 1.14 ]
Subtotal (95% CI) 2212 2242 60.4 % 0.73 [ 0.62, 0.87 ]
Total events: 227 (Invasive), 326 (Conservative)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.19, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.69 (P = 0.00023)
2 Female
FRISC-II 36/344 33/398 8.5 % 1.26 [ 0.80, 1.98 ]
Italian Elderly ACS 38/78 44/78 14.3 % 0.86 [ 0.64, 1.17 ]
OASIS 5 13/92 10/92 3.5 % 1.30 [ 0.60, 2.81 ]
RITA-3 17/350 30/332 5.8 % 0.54 [ 0.30, 0.96 ]
TACTICS-TIMI 18 26/395 35/362 7.5 % 0.68 [ 0.42, 1.11 ]
Subtotal (95% CI) 1259 1262 39.6 % 0.87 [ 0.65, 1.16 ]
Total events: 130 (Invasive), 152 (Conservative)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.34, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 3471 3504 100.0 % 0.78 [ 0.67, 0.91 ]
Total events: 357 (Invasive), 478 (Conservative)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.95, df = 8 (P = 0.11); I2 =38%
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.13. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 13 Late death or non-fatal myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 13 Late death or non-fatal myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 76/604 63/596 23.0 % 1.19 [ 0.87, 1.63 ]
Subtotal (95% CI) 604 596 23.0 % 1.19 [ 0.87, 1.63 ]
Total events: 76 (Invasive), 63 (Conservative)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 217/1222 270/1235 41.3 % 0.81 [ 0.69, 0.95 ]
RITA-3 142/895 178/915 35.7 % 0.82 [ 0.67, 1.00 ]
Subtotal (95% CI) 2117 2150 77.0 % 0.81 [ 0.72, 0.92 ]
Total events: 359 (Invasive), 448 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Total (95% CI) 2721 2746 100.0 % 0.89 [ 0.73, 1.08 ]
Total events: 435 (Invasive), 511 (Conservative)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.87, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 4.87, df = 1 (P = 0.03), I2 =79%
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Analysis 1.14. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 14 Intermediate refractory angina.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 14 Intermediate refractory angina
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 85/604 77/596 19.2 % 1.09 [ 0.82, 1.45 ]
LIPSIA-NSTEMI 13/400 20/200 7.2 % 0.33 [ 0.17, 0.64 ]
TACTICS-TIMI 18 430/1114 660/1106 28.5 % 0.65 [ 0.59, 0.71 ]
Subtotal (95% CI) 2118 1902 54.9 % 0.67 [ 0.42, 1.08 ]
Total events: 528 (Invasive), 757 (Conservative)
Heterogeneity: Tau2 = 0.14; Chi2 = 16.17, df = 2 (P = 0.00031); I2 =88%
Test for overall effect: Z = 1.66 (P = 0.097)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 256/1222 455/1235 26.9 % 0.57 [ 0.50, 0.65 ]
RITA-3 58/895 106/915 18.2 % 0.56 [ 0.41, 0.76 ]
Subtotal (95% CI) 2117 2150 45.1 % 0.57 [ 0.50, 0.64 ]
Total events: 314 (Invasive), 561 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 9.22 (P < 0.00001)
Total (95% CI) 4235 4052 100.0 % 0.64 [ 0.52, 0.79 ]
Total events: 842 (Invasive), 1318 (Conservative)
Heterogeneity: Tau2 = 0.04; Chi2 = 20.90, df = 4 (P = 0.00033); I2 =81%
Test for overall effect: Z = 4.19 (P = 0.000028)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.15. Comparison 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa
receptor use, Outcome 15 Intermediate rehospitalisation.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 1 All studies undertaken in the stent era regardless of glycoprotein IIb/IIIa receptor use
Outcome: 15 Intermediate rehospitalisation
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Routine glycoprotein IIb/IIIa receptor antagonist use
ICTUS 44/604 64/596 16.8 % 0.68 [ 0.47, 0.98 ]
LIPSIA-NSTEMI 28/400 9/200 6.2 % 1.56 [ 0.75, 3.23 ]
TACTICS-TIMI 18 123/1114 152/1106 26.3 % 0.80 [ 0.64, 1.00 ]
Subtotal (95% CI) 2118 1902 49.4 % 0.83 [ 0.61, 1.14 ]
Total events: 195 (Invasive), 225 (Conservative)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.95, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.15 (P = 0.25)
2 No routine glycoprotein IIb/IIIa receptor antagonist use
FRISC-II 451/1222 704/1235 36.6 % 0.65 [ 0.59, 0.71 ]
Italian Elderly ACS 26/154 27/159 11.6 % 0.99 [ 0.61, 1.62 ]
VINO 4/64 6/67 2.5 % 0.70 [ 0.21, 2.36 ]
Subtotal (95% CI) 1440 1461 50.6 % 0.71 [ 0.54, 0.94 ]
Total events: 481 (Invasive), 737 (Conservative)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 2.42 (P = 0.015)
Total (95% CI) 3558 3363 100.0 % 0.77 [ 0.63, 0.94 ]
Total events: 676 (Invasive), 962 (Conservative)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.87, df = 5 (P = 0.05); I2 =54%
Test for overall effect: Z = 2.60 (P = 0.0092)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 2.1. Comparison 2 Safety endpoints, Outcome 1 Procedure-related myocardial infarction.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 2 Safety endpoints
Outcome: 1 Procedure-related myocardial infarction
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FRISC-II 66/1222 36/1235 36.3 % 1.85 [ 1.24, 2.76 ]
ICTUS 72/604 36/596 39.1 % 1.97 [ 1.34, 2.90 ]
Italian Elderly ACS 3/154 4/159 2.6 % 0.77 [ 0.18, 3.40 ]
LIPSIA-NSTEMI 44/400 14/200 17.3 % 1.57 [ 0.88, 2.80 ]
RITA-3 15/895 4/915 4.8 % 3.83 [ 1.28, 11.51 ]
Total (95% CI) 3275 3105 100.0 % 1.87 [ 1.47, 2.37 ]
Total events: 200 (Invasive), 94 (Conservative)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.43, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 5.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Safety endpoints, Outcome 2 Bleeding.
Review: Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Comparison: 2 Safety endpoints
Outcome: 2 Bleeding
Study or subgroup Invasive Conservative Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FRISC-II 112/1222 81/1235 38.3 % 1.40 [ 1.06, 1.84 ]
Italian Elderly ACS 2/154 1/159 1.4 % 2.06 [ 0.19, 22.54 ]
LIPSIA-NSTEMI 2/400 2/200 2.1 % 0.50 [ 0.07, 3.52 ]
OASIS 5 9/92 2/92 3.5 % 4.50 [ 1.00, 20.26 ]
RITA-3 73/895 32/915 27.3 % 2.33 [ 1.56, 3.50 ]
TACTICS-TIMI 18 61/1114 36/1106 27.4 % 1.68 [ 1.12, 2.52 ]
Total (95% CI) 3877 3707 100.0 % 1.73 [ 1.30, 2.31 ]
Total events: 259 (Invasive), 154 (Conservative)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.41, df = 5 (P = 0.19); I2 =33%
Test for overall effect: Z = 3.72 (P = 0.00020)
Test for subgroup differences: Not applicable
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Table 1. Detailed characteristics of included studies, rates of angiography and revascularisation
Study char-
acteristic
TACTICS-
TIMI 18
ICTUS RITA-3 FRISC-II VINO Italian
Elderly
ACS
LIPSIA-
NSTEMI
OASIS 5
Year of pub-
lication
2001 2005 2002 1999 2001 2012 2012 2012
Total num-
ber of partic-
ipants
2220 1200 1810 2457 131 313 602 184
Stent use in
invasive arm
%
83 88 88 61 47 50 73 52
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Table 1. Detailed characteristics of included studies, rates of angiography and revascularisation (Continued)
Men % 66 74 62 70 80 50 67 0
Mean age 62 62 63 65 66 82 70 68
Trial
duration
6 months 4 years 5 years 5 years 6 months 1 year 6 months 2 years
Diabetes
mellitus %
28 14 13 13 25 36 38 25
Myocar-
dial infarc-
tion (MI) on
trial enrol-
ment %
54 100 75 58 100 100 100 67
Previous MI
%
29 23 28 23 26 31 20 22
ST depres-
sion %
39 48 37 46 47 NA 62 47
Mortality in
conserva-
tively man-
aged partici-
pants at end
of follow-up
% (note dif-
ferent trial
durations)
3.5 7.7 14 10.1 13.4 13.8 6.5 2.2
Mortality in
conserva-
tively man-
aged partici-
pants ex-
pressed as an
aver-
age mortal-
ity per year
of follow-up
%/year
7.0 1.9 2.8 2.0 26.8 13.8 13 1.1
MI rate
in conserva-
tively man-
aged partici-
pants at end
6.9 12.3 (as per
trial defini-
tion)
6.2 17.7 14.9 10.7 11.5 13.3
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Table 1. Detailed characteristics of included studies, rates of angiography and revascularisation (Continued)
of follow-up
% (note dif-
ferent trial
durations)
Glyco-
protein 2b/
3a receptor
antagonist
use in inva-
sive arm %
94 94 9 10 0 17 99 12
Revascu-
larization at
end of fol-
low-up inva-
sive/conser-
vative %
61/44 81/58 61/38 80/52 78/39 58/31 84/70 64/49
Difference
in revascu-
larization
rates at end
of follow-up
between the
2 strategies
%
17 23 23 28 39 27 14 15
Percent-
age of revas-
cular-
ization pro-
cedures in
the invasive
group being
CABG %
22 24 42 41 35 7 10 21
Med-
ical co-inter-
ventions (%
of par-
ticipants en-
rolled)
Aspirin: 98;
unfraction-
ated
heparin: 99;
beta-
blocker: 82;
statin:
52; clopido-
grel: 0 (this
was a crite-
rion for ex-
clusion)
Aspirin: 100
as per proto-
col, enoxa-
parin: 100 as
per pro-
tocol, statin:
92, clopido-
grel: 55
Aspirin: 92;
enoxaparin:
84; unfrac-
tionated
heparin: 11;
beta-
blocker: 72;
calcium
channel an-
tagonist: 35;
ACE in-
hibitor: 18;
Aspirin: 93;
dalteparin
50; unfrac-
tionated
heparin: 50;
beta-
blocker: 79;
calcium
channel an-
tagonist: 20;
statin: 56
Aspirin: 100
as per proto-
col, heparin:
100
as per pro-
tocol; beta-
blocker: 76;
calcium
channel an-
tagonist:
9; ACE in-
hibitor: 47;
During
index ad-
mission:
aspirin:
96; ticlopi-
dine: 3.2;
clopidogrel:
90; unfrac-
tionated
heparin:
24; enoxa-
parin: 50;
Beta-
blockers: 99;
ACEi/ARB:
99; Asprin:
100; clopi-
dogrel/pra-
sugrel: 99;
statins: 98;
tirofiban: 99
Aspirin:
99; clopido-
grel: or ticlo-
pedin:
81; dual an-
tiplatelet
therapy: 80;
UFH: 10;
enoxaparin:
50; fonda-
parinux:
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Table 1. Detailed characteristics of included studies, rates of angiography and revascularisation (Continued)
statin: 45 statin: 43 bivalirudin:
2.5; fonda-
parinux: 7;
at discharge:
aspirin:
91; ticlo-
pidine: 2;
clopidogrel:
76; beta-
blockers:
60; ACEi:
80; statins:
80
50; ACE in-
hibitor
or ARB: 76;
beta-
blocker: 94;
lipid-lower-
ing drug: 87
Table 2. Definitions of myocardial infarction in the included studies
Study name Definition for non-pro-
cedural myocardial in-
farction (MI)
Definition of procedu-
ral MI
More than one defini-
tion of MI?
Definition ofMI used in
this review
RITA-3 Clinical symptoms, ECG
changes and CK-MB or
Toponin > 2 x upper limit
of normal > 24 hours pos-
trandomisation
Clinical symptoms, ECG
changes and CK-MB or
Toponin > 2 x upper limit
of normal > 24 hours pos-
trandomisation
Yes As per trial definition
ICTUS CK-MB > upper limit of
normal or a 50% decline
from a peak value fol-
lowed by subsequent rise
to a value greater than the
upper limit of normal. An
increased troponin above
the upper limit of normal
was also used beyond one
year of follow-up
CK-MB > upper limit of
normal or a 50% decline
from a peak value fol-
lowed by subsequent rise
to a value greater than
the upper limit of normal.
NewQwaves on the elec-
trocardiogram were used
to define MI associated
with coronary artery by-
pass grafting
Yes In various publications,
the trial authors report
the MI end point as the
following
1. Total MI.
2. Spontaneous MI.
3. Procedural MI.
We utilized spontaneous
MI for our MI endpoint,
death/spontaneous MI
for our death or MI com-
posite and procedural MI
is reported as a safety end-
point. Since the prognos-
tic value of peri-procedu-
ral infarctions is still de-
bated, ’spontaneous’ MI
is our preferred endpoint
since this allows for con-
sistencywith the other tri-
als
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Table 2. Definitions of myocardial infarction in the included studies (Continued)
TACTICS-TIMI 18 CK-MB > upper limit of
normal or > 50% over
previous
CK-MB > 3 times upper
limit of normal or > 50%
over previous
No As per trial definition
Italian Elderly ACS Cardiac ischaemic symp-
toms at rest within 42
hours before randomisa-
tion, together with Is-
chemic
ECG changes (transient
or persistent ST-segment
elevation or depression >
0.5mm but < 1 mm in
the case of ST-elevation,
or persistent and definite
T-wave inversion > 1 mm
in at least 2 contiguous
leads) and/or any eleva-
tion of CK-MB or cTn (>
upper limit of normal)
Recurrent infarc-
tion within first 72 hours:
Ischemic ECG changes
(new Q-waves > 0.04 s
in 2 or more contigu-
ous leads which is not an
ambiguous change from
baseline) CK-MB > up-
per limit of normal and
increased > 50% over pre-
vious value
Following PCI: CK-MB
elevation > 3 times upper
limit of normal and in-
creased by at least 50%
over the previous value
In 72 hours following
CABG: both biomarker
and ECG criteria if the
CK-MB is > 5 times up-
per limit of normal but
< 10 times upper limit
of normal; if the cardiac
markers are > 10 times
upper limit of normal,
ECH criteria are not re-
quired
No As per trial definition
LIPSIA-NSTEMI Ischaemic symptoms that
were increasing or oc-
curred at rest, with the last
episode < 24 hours be-
fore randomisation plus
elevated troponin T level
≥ 0.1 ng/mL
In-hospital re-MI was de-
fined by the occurrence
of any of the following:
new Q waves in ≥ 2
contiguous leads plus is-
chaemic symptoms > 20
mins; or new ST-segment
elevation in ≥ 2 contigu-
ous leads plus ischaemic
symptoms > 20 mins; or
elevation of CK-MB > 5
upper limit of normal in
those with CK-MB > 5
times upper limit of nor-
mal at randomisation an
increase > 50% was re-
No As per trial definition
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Table 2. Definitions of myocardial infarction in the included studies (Continued)
quired for re-MI defini-
tion
VINO Recurrent is-
chaemic chest pain lasting
> 20 minutes, new ECG
changes and CK-MB > 1.
5 times the upper limit
of normal after 72 hours
postrandomisation
Recurrent is-
chaemic chest pain lasting
> 20 minutes, new ECG
changes and CK-MB > 1.
5 times the upper limit
of normal after 72 hours
postrandomisation
No As per trial definition
FRISC-II Two or three of the
following criteria: chest
pain, ECGchanges or ele-
vated markers of myocar-
dial damage. Marker def-
initions: CK-MB mass >
upper limit of normal or
CK, CK-B, CK-MB ac-
tivity > 2 times upper
limit of normal in 1 sam-
ple of CK-MB activity >
upper limit of normal in
2 samples
Either 2 or 3 of the
following criteria: chest
pain, ECG changes or el-
evated markers of my-
ocardial damage. Marker
definitions: CK-MBmass
> 1.5 times upper limit
of normal or CK, CK-B,
CK-MBactivity > 3 times
upper limit of normal in 1
sample of CK-MB activ-
ity > 2 times upper limit
of normal in 2 samples
No As per trial definition
OASIS 5 Typical rise and fall of
biochemical marker of
myocardial necrosis (in-
cluding troponin, CK-
MB, CK) to greater than
2 x ULN (if markers
were already elevated, >
50% of the lowest recov-
ery biomarker level from
the index infarction) and
at least one of the follow-
ing
1. Ischaemic
symptoms.
2. Development of
pathological Q waves on
ECG.
3. ECG changes
indicative of ischaemia
(ST-segment elevation or
depression).
4. Coronary artery
intervention.
5. Findings of an
Typical rise and fall of
biochemical marker of
myocardial necrosis (in-
cluding troponin, CK-
MB, CK) to greater than
3 x ULN if within 48
hours of PCI or 5 x ULN
if within 48 hours of
CABG and at least one of
the following
1. Ischaemic
symptoms.
2. Development of
pathological Q waves on
ECG.
3. ECG changes
indicative of ischaemia
(ST-segment elevation or
depression).
4. Coronary artery
intervention.
5. Findings of an
acute MI at autopsy.
No As per trial definition
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Table 2. Definitions of myocardial infarction in the included studies (Continued)
acute MI at autopsy.
MI = myocardial infarction
A P P E N D I C E S
Appendix 1. Search strategies 2008
CENTRAL on the Cochrane Library
#1 MeSH descriptor Angina, Unstable explode all trees
#2 unstable next angina in All Text
#3 coronary next syndrome* in All Text
#4 MeSH descriptor Myocardial Infarction explode all trees
#5 myocardial next infarct* in All Text
#6 heart next infarct* in All Text
#7 nstemi in All Text
#8 unstable next coronary in All Text
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10 (ischaemi* in All Text near/6 guid* in All Text)
#11 (ischemi* in All Text near/6 guid* in All Text)
#12 (early in All Text near/6 invasive in All Text)
#13 (invasive in All Text near/6 conservative in All Text)
#14 (angiography in All Text near/6 invasive in All Text)
#15 (angiography in All Text near/6 conservative in All Text)
#16 (ischemi* in All Text near/6 strateg* in All Text)
#17 (ischaemi* in All Text near/6 strateg* in All Text)
#18 (conservative in All Text near/6 strateg* in All Text)
#19 (conservative in All Text near/6 therap* in All Text)
#20 (conservative in All Text near/6 treatment* in All Text)
#21 (conservative in All Text near/6 management in All Text)
#22 (interventional in All Text near/6 strateg* in All Text)
#23 (interventional in All Text near/6 therap* in All Text)
#24 (interventional in All Text near/6 treatment* in All Text)
#25 (interventional in All Text near/6 management in All Text)
#26 (invasive in All Text near/6 strateg* in All Text)
#27 (invasive in All Text near/6 therap* in All Text)
#28 (invasive in All Text near/6 treatment* in All Text)
#29 (invasive in All Text near/6 management in All Text)
#30 (triage in All Text near/6 angiograph* in All Text)
#31 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19)
#32 (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30)
#33 (#31 or #32)
#34 (#9 and #33)
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MEDLINE (on Ovid)
1 Myocardial Infarction/
2 exp Angina, Unstable/
3 Acute Coronary Syndrome/
4 unstable angina$.tw.
5 coronary syndrome$.tw.
6 myocardial infarction$.tw.
7 or/1-6
8 (intervention$ adj2 (strateg$ or therapy or therapies or treatment$)).tw.
9 (conservative adj2 (strateg$ or therapy or therapies or treatment$)).tw.
10 (invasive adj2 (strateg$ or therapy or therapies or treatment$)).tw.
11 8 or 9 or 10
12 7 and 11 (
13 (isch?emia adj2 guide$).tw.
14 ((invasive or conservative) adj2 management).tw.
15 11 or 13 or 14
16 7 and 15
17 randomized controlled trial.pt.
18 controlled clinical trial.pt.
19 Randomized controlled trials/
20 random allocation/
21 double blind method/
22 single-blind method/
23 or/17-22
24 exp animal/ not humans/
25 23 not 24
26 clinical trial.pt.
27 exp Clinical Trials as Topic/
28 (clin$ adj25 trial$).ti,ab.
29 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
30 placebos/
31 placebo$.ti,ab.
32 random$.ti,ab.
33 research design/
34 or/26-33
35 34 not 24
36 35 not 25
37 comparative study.pt.
38 exp evaluation studies/
39 follow up studies/
40 prospective studies/
41 (control$ or prospectiv$ or volunteer$).ti,ab.
42 or/37-41
43 42 not 24
44 43 not (25 or 36)
45 25 or 36 or 44
46 45 and 16
EMBASE (on Ovid)
1 exp heart infarction/
2 exp unstable angina pectoris/
3 Acute Coronary Syndrome/
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4 unstable angina$.tw.
5 coronary syndrome$.tw.
6 myocardial infarct$.tw.
7 heart infarct$.tw.
8 nstemi.tw.
9 unstable coronary.tw.
10 or/1-8
11 (isch?emi$ adj3 guid$).tw.
12 (early adj3 invasive$).tw.
13 (early adj3 conservative$).tw.
14 (isch?emi$ adj3 strateg$).tw.
15 (conservative adj3 (strateg$ or therapy or therapies or treatment$ or management)).tw.
16 (interventional adj3 (strateg$ or therapy or therapies or treatment$ or management)).tw.
17 (invasive adj3 (strateg$ or therap$ or treatment$ or management)).tw.
18 (triage adj3 angiograph$).tw.
19 or/11-18
20 10 and 19
21 controlled study/
22 clinical trial/
23 major clinical study/
24 random$.tw.
25 randomized controlled trial/
26 trial$.tw.
27 compar$.tw.
28 control$.tw.
29 follow-up.tw.
30 blind$.tw.
31 double blind procedure/
32 placebo$.tw.
33 clinical article/
34 placebo/
35 doubl$.tw.
36 or/21-35
37 20 and 36
38 limit 37 to yr=“1996 - 2008”
MEDLINE (Ovid) search for 2006 review version
#1 explode ’Myocardial-Infarction’ /
#2 explode ’Angina-Unstable’ /
#3 unstable angina$
#4 coronary syndrome$
#5 myocardial infarct$
#6 myocardial infarction heart infarct$
#7 nstemi
#8 unstable coronary
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 ischaemi$ adj3 guid$
#11 ischemi$ adj3 guid$
#12 early adj3 invasive
#13 invasive adj3 conservative
#14 ischemi$ adj3 strateg$
#15 ischaemi$ adj3 strateg$
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#16 conservative adj3 strateg$
#17 conservative adj3 therap$
#18 conservative adj3 treatment$
#19 conservative adj3 management
#20 interventional adj3 strateg$
#21 interventional adj3 therap$
#22 interventional adj3 treatment$
#23 interventional adj3 management
#24 invasive adj3 strateg$
#25 invasive adj3 therap$
#26 invasive adj3 treatment$
#27 invasive adj3 management
#28 triage adj3 angiograph$
#29 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28
#30 #9 and #29
We used a randomised controlled trial (RCT) filter as described in the Cochrane Handbook for Systematic Reviews of Interventions
(Lefebvre 2011).
Appendix 2. Search strategies 2015
We applied the RCT filter forMEDLINE is the Cochrane sensitivity-maximising RCT filter, and for EMBASE, terms as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
CENTRAL on the Cochrane Library
#1 MeSH descriptor: [Myocardial Infarction] explode all trees
#2 MeSH descriptor: [Acute Coronary Syndrome] this term only
#3 MeSH descriptor: [Angina, Unstable] explode all trees
#4 unstable next angina*
#5 coronary next syndrome*
#6 myocardial next infarct*
#7 heart next infarct*
#8 nstemi
#9 unstable next coronary
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 (interven* near/6 (strateg* or therap* or treatment* or management))
#12 (conservative near/6 (strateg* or therap* or treatment* or management))
#13 (invasive near/6 (strateg* or therap* or treatment* or management))
#14 ((ischaemi* or ischemi*) near/6 (guid* or strateg*))
#15 early near/6 invasive
#16 invasive near/6 conservative
#17 angiography near/6 (invasive or conservative)
#18 triage near/6 angiograph*
#19 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 #10 and #19
Publication years 2008-2015
MEDLINE (on Ovid)
1. Myocardial Infarction/
2. exp Angina, Unstable/
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3. Acute Coronary Syndrome/
4. unstable angina$.tw.
5. coronary syndrome$.tw.
6. myocardial infarction$.tw.
7. heart infarct*.tw.
8. nstemi.tw.
9. (unstable adj2 coronary).tw.
10. or/1-9
11. (interven$ adj2 (strateg$ or therap$ or treatment$ or management)).tw.
12. (conservative adj2 (strateg$ or therap$ or treatment$ or management)).tw.
13. (invasive adj2 (strateg$ or therap$ or treatment$ or management)).tw.
14. (early adj2 invasive).tw.
15. ((ischaemi* or ischemi*) adj4 (guid* or strateg*)).tw.
16. (invasive adj4 conservative).tw.
17. (angiography adj4 (invasive or conservative)).tw.
18. (triage adj4 angiograph*).tw.
19. or/11-18
20. 10 and 19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. drug therapy.fs.
26. randomly.ab.
27. trial.ab.
28. groups.ab.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. exp animals/ not humans.sh.
31. 29 not 30
32. 20 and 31
33. limit 32 to yr=“2008 -Current”
EMBASE (on Ovid)
1. exp heart infarction/
2. exp unstable angina pectoris/
3. acute coronary syndrome/
4. unstable angina$.tw.
5. coronary syndrome$.tw.
6. myocardial infarct$.tw.
7. heart infarct*.tw.
8. nstemi.tw.
9. (unstable adj2 coronary).tw.
10. or/1-9
11. (conservative adj3 (strateg$ or therap$ or treatment$ or management)).tw.
12. (interven$ adj3 (strateg$ or therap$ or treatment$ or management)).tw.
13. (invasive adj3 (strateg$ or therap$ or treatment$ or management)).tw.
14. (early adj2 invasive).tw.
15. ((ischaemi* or ischemi*) adj4 (guid* or strateg*)).tw.
16. (invasive adj4 conservative).tw.
17. (triage adj4 angiograph*).tw.
18. (angiography adj4 (invasive or conservative)).tw.
19. or/11-18
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20. 10 and 19
21. random$.tw.
22. factorial$.tw.
23. crossover$.tw.
24. cross over$.tw.
25. cross-over$.tw.
26. placebo$.tw.
27. (doubl$ adj blind$).tw.
28. (singl$ adj blind$).tw.
29. assign$.tw.
30. allocat$.tw.
31. volunteer$.tw.
32. crossover procedure/
33. double blind procedure/
34. randomized controlled trial/
35. single blind procedure/
36. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
37. (animal/ or nonhuman/) not human/
38. 36 not 37
39. 20 and 38
40. limit 39 to yr=“2008 -Current”
WH A T ’ S N E W
Last assessed as up-to-date: 25 August 2015.
Date Event Description
26 August 2015 New search has been performed Three new studies met the inclusion criteria of this
Cochrane review
26 August 2015 New citation required and conclusions have changed We re-ran the search strategies for the last published
review (with minor amendments). We included new
articles related to three studies, Italian Elderly ACS,
LIPSIA-NSTEMI and OASIS 5, in the meta-analysis.
This resulted in a change to the review conclusions
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 3, 2006
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Date Event Description
27 February 2009 New citation required but conclusions have not
changed
Change of review authors.
27 February 2009 New search has been performed We updated the literature search to February 2008, and
identified 22 additional potentially relevant references.
We excluded five references that reported on two stud-
ies. The remaining 14 references were additional re-
ports of already included studies. We added long-term
follow-up data from the ICTUS trial.
27 October 2008 Amended We converted to a new review format.
5 March 2006 New citation required and conclusions have changed We made substantive amendments to the review.
C O N T R I B U T I O N S O F A U T H O R S
JPF is the primary author of the review update, and extracted and analysed data (2008 to 2015). JN screened results and prepared
the ’Summary of findings’ tables and performed the GRADE assessments. CNA and IAS designed the protocol and provided advice
regarding the final manuscript. DLW is an author of the review update, and extracted and analysed the data (2008 to 2015).
D E C L A R A T I O N S O F I N T E R E S T
JPF has no known conflicts of interest.
JN has no known conflicts of interest.
IAS has no known conflicts of interest.
CNA received travel grants from Boston Scientific, J&J, Medtronic, MSD and Eli Lilly.
DLW has been an investigator on a number of clinical research trials in the area of ACS and PCI. All funds in this regard have been
paid to the institution to cover research costs. He did some paid proctoring work in the field of TAVI, which might not be directly
relevant to this work.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We modified the title of the review to reflect evolution in practice. “Routine invasive” replaces “early invasive” and “selective invasive”
replaces “conservative”. We used the GRADE methodology to assess the quality of evidence and included ’Summary of findings’ tables,
though we did not specify this in the published Cochrane protocol (Hoenig 2004).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Angina, Unstable [mortality; surgery; ∗therapy]; Angioplasty, Balloon, Coronary [∗adverse effects]; Cause of Death; Coronary An-
giography; Coronary Artery Disease [therapy]; Myocardial Infarction [mortality; surgery; ∗therapy]; Platelet Glycoprotein GPIIb-IIIa
Complex [antagonists & inhibitors]; Randomized Controlled Trials as Topic; Sex Factors; Stents
MeSH check words
Female; Humans; Male
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